{"content":"<li class=\"n-box-item date-title\" data-end=\"1566359999\" data-start=\"1566273600\" data-txt=\"Monday, December 23, 2019\">Tuesday, August 20, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3493459\" data-ts=\"1566342081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WTRH\" target=\"_blank\">WTRH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493459-waitrplus-12_3-after-fertitta-buys-1m-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Waitr +12.3% after Fertitta buys 1M shares</a></h4><ul>   <li>Waitr Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/WTRH' title='Waitr Holdings Inc.'>WTRH</a>) has moved <font color=\"green\">up 12.3%</font> after hours after a pair of insider buys anchored by billionaire Tilman Fertitta.</li>    <li>Fertitta (a director) disclosed purchases <a href=\"https://seekingalpha.com/filing/4609738\" target=\"_blank\">aggregating to 1M shares</a>: 275,000 at average price of $1.437, 450,000 at $1.429 and 275,000 more at $1.41. That makes up his beneficial direct ownership; he also holds 4M shares indirectly through Fertitta Entertainment.</li>    <li>President Joseph Stough <a href=\"https://seekingalpha.com/filing/4609004\" target=\"_blank\">bought 45,000 shares</a> at an average price of $1.473. That leaves him with direct beneficial ownership of 902,711 shares.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3493459\" data-linked=\"Waitr +12.3% after Fertitta buys 1M shares\" data-tweet=\"$WTRH - Waitr +12.3% after Fertitta buys 1M shares https://seekingalpha.com/news/3493459-waitrplus-12_3-after-fertitta-buys-1m-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3493459-waitrplus-12_3-after-fertitta-buys-1m-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493457\" data-ts=\"1566341670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LXRX\" target=\"_blank\">LXRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493457-lexicon-pharmaplus-4_6-ceo-buys-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lexicon Pharma +4.6% as CEO buys shares</a></h4><ul>   <li>Lexicon Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/LXRX' title='Lexicon Pharmaceuticals, Inc.'>LXRX</a>) is <font color=\"green\">up 4.6%</font> after hours, rebounding off a 6.4% decline today, following disclosure that its president and CEO, Lonnel Coats, made several stock purchases over the past couple of business days.</li>    <li>In a set of <a href=\"https://seekingalpha.com/filing/4609775\" target=\"_blank\">eight listed transactions</a>, Coats bought 40,000 shares of the company's stock.</li>    <li>Following those, Coats lists a beneficial ownership of 127,539 shares -- about $168,351 worth at current prices.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493457\" data-linked=\"Lexicon Pharma +4.6% as CEO buys shares\" data-tweet=\"$LXRX - Lexicon Pharma +4.6% as CEO buys shares https://seekingalpha.com/news/3493457-lexicon-pharmaplus-4_6-ceo-buys-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3493457-lexicon-pharmaplus-4_6-ceo-buys-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493456\" data-ts=\"1566341291\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HA\" target=\"_blank\">HA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493456-hawaiian-holdingsminus-2_5-stifel-cuts-to-sell\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hawaiian Holdings -2.5% as Stifel cuts to Sell</a></h4><ul>   <li>Hawaiian Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/HA' title='Hawaiian Holdings, Inc.'>HA</a>) is <font color=\"red\">2.5% lower</font> after hours following a downgrade by Stifel, to Sell from a previous Buy.</li>    <li>The firm cites risk to 2020 EPS and trims its price target to $20 from $30, implying 21% downside from today's close.</li>    <li>Sell-side analysts <a href=\"https://seekingalpha.com/symbol/HA/ratings/sell-side-ratings\" target=\"_blank\">rate the stock a Hold</a> overall, and it has a <a href=\"https://seekingalpha.com/symbol/HA/ratings/quant-ratings\" target=\"_blank\">Quant Rating of Neutral</a>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3493456\" data-linked=\"Hawaiian Holdings -2.5% as Stifel cuts to Sell\" data-tweet=\"$HA - Hawaiian Holdings -2.5% as Stifel cuts to Sell https://seekingalpha.com/news/3493456-hawaiian-holdingsminus-2_5-stifel-cuts-to-sell?source=tweet\" data-url=\"https://seekingalpha.com/news/3493456-hawaiian-holdingsminus-2_5-stifel-cuts-to-sell\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493455\" data-ts=\"1566341055\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LEDS\" target=\"_blank\">LEDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493455-semiledsplus-19-on-2m-share-purchase-offer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SemiLEDs +19% on $2M share purchase offer</a></h4><ul>   <li>SemiLEDs (NASDAQ:<a href='https://seekingalpha.com/symbol/LEDS' title='SemiLEDs Corporation'>LEDS</a>) has <font color=\"green\">gained 19.4%</font> after hours following an offer it received to buy 680,000 shares.</li>    <li>In a <a href=\"https://seekingalpha.com/filing/4609407\" target=\"_blank\">filing</a>, the company notes it received the offer to buy that quantity at $3 each (a 35% premium) from individual investor Xian Chang Ma (chairman/CEO of Shandong Tengjunxiang Biotechnology), in China.</li>    <li>The 680K shares make up about 19% of currently outstanding shares.</li>    <li>The deal's contingent on board acceptance and a definitive stock purchase agreement. On closing, the board expects to nominate Ma to a director's seat.</li>    <li>SemiLEDs says its board will decide on the offer by Aug. 30.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493455\" data-linked=\"SemiLEDs +19% on $2M share purchase offer\" data-tweet=\"$LEDS - SemiLEDs +19% on $2M share purchase offer https://seekingalpha.com/news/3493455-semiledsplus-19-on-2m-share-purchase-offer?source=tweet\" data-url=\"https://seekingalpha.com/news/3493455-semiledsplus-19-on-2m-share-purchase-offer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493446\" data-ts=\"1566336955\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493446-cree-fanh-lzb-and-urbn-among-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CREE, FANH, LZB and URBN among after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/YPF' title='YPF Sociedad Anónima'>YPF</a> <font color=\"green\">+4.2%</font>. <a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color=\"green\">+4.2%</font>. <a href='https://seekingalpha.com/symbol/LL' title='Lumber Liquidators Holdings, Inc.'>LL</a> <font color=\"green\">+3.5%</font>. <a href='https://seekingalpha.com/symbol/LZB' title='La-Z-Boy Incorporated'>LZB</a> <font color=\"green\">+3.4%. </font><a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a> <font color=\"green\">+1.5%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/NDSN' title='Nordson Corporation'>NDSN</a> <font color=\"red\">-7.5%</font>. <a href='https://seekingalpha.com/symbol/CREE' title='Cree, Inc.'>CREE</a> <font color=\"red\">-6.9%</font>. <a href='https://seekingalpha.com/symbol/CMRE' title='Costamare Inc.'>CMRE</a> <font color=\"red\">-3.3%</font>. <a href='https://seekingalpha.com/symbol/PDLI' title='PDL BioPharma, Inc.'>PDLI</a> <font color=\"red\">-2.7%. </font><a href='https://seekingalpha.com/symbol/GOL' title='Gol Linhas Aéreas Inteligentes S.A.'>GOL</a> <font color=\"red\">-1.9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493446\" data-linked=\"CREE, FANH, LZB and URBN among after hour movers\" data-tweet=\"$YPF $URBN $LL - CREE, FANH, LZB and URBN among after hour movers https://seekingalpha.com/news/3493446-cree-fanh-lzb-and-urbn-among-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3493446-cree-fanh-lzb-and-urbn-among-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493434\" data-ts=\"1566333906\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOL\" target=\"_blank\">TOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493434-toll-brothersplus-2_9-q3-beats-ups-lower-end-of-fy-guidance-range\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toll Brothers +2.9% as Q3 beats; ups lower end of FY guidance range</a></h4><ul><li>Toll Brothers (NYSE:<a href='https://seekingalpha.com/symbol/TOL' title='Toll Brothers, Inc.'>TOL</a>)<font color=\"green\"> climbs 2.9%</font> in after-hours trading after nudging up the lower end of its<a href=\"https://seekingalpha.com/pr/17608976-toll-brothers-reports-fy-2019-3rd-quarter-results\" target=\"_blank\"> fiscal 2019 guidance range</a> for deliveries.</li><li>Sees delivering 7,800-8,100 units vs. 7,700-8,100 in its previous earnings release.</li><li>Sees average price of $860K-$880K vs. $855K-$880K.</li><li>Repeats guidance for FY 2019 adjusted home sales gross margin at 23.0%; SG&amp;A, as a percentage of home sales revenue, of ~10.4%.</li><li>Sees FY2019 tax rate of 25.6%.</li><li>Fiscal Q3 EPS of $1.00 beats the average analyst estimate of 81 cents and compares with $1.26 in the year-ago quarter.</li><li>Home sales revenue for the quarter ended July 31, 2019 was $1.76B, down 8% Y/Y; home building deliveries of 1,994, fell 11%.</li><li>\"While our third quarter contracts were down modestly, we are off to a good start in our fourth quarter,\" said Chairman and CEO Douglas C. Yearley Jr. \"Low mortgage rates, a limited supply of new and existing homes, and a strong employment picture are providing tailwinds.\"</li><li><a href=\"https://investors.tollbrothers.com/\" target=\"_blank\">Conference call</a> on Aug. 21 at 11:00 AM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3493425-toll-brothers-eps-beats-0_17-beats-revenue\" target=\"_blank\">Toll Brothers EPS beats by $0.17, beats on revenue</a> (Aug. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3493434\" data-linked=\"Toll Brothers +2.9% as Q3 beats; ups lower end of FY guidance range\" data-tweet=\"$TOL - Toll Brothers +2.9% as Q3 beats; ups lower end of FY guidance range https://seekingalpha.com/news/3493434-toll-brothersplus-2_9-q3-beats-ups-lower-end-of-fy-guidance-range?source=tweet\" data-url=\"https://seekingalpha.com/news/3493434-toll-brothersplus-2_9-q3-beats-ups-lower-end-of-fy-guidance-range\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493433\" data-ts=\"1566333667\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FANH\" target=\"_blank\">FANH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493433-fanhua-reports-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fanhua reports Q2 results</a></h4><ul><li>Fanhua (NASDAQ:<a href='https://seekingalpha.com/symbol/FANH' title='Fanhua Inc.'>FANH</a>): Q2 Non-GAAP EPADS of RMB2.51; GAAP EPADS of RMB1.78.</li><li>Revenue of RMB898.42M (-7.6% Y/Y)</li><li>Shares <font color=\"green\">+1.75%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17608981-fanhua-reports-second-quarter-first-half-2019-unaudited-financial-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3493433\" data-linked=\"Fanhua reports Q2 results\" data-tweet=\"$FANH - Fanhua reports Q2 results https://seekingalpha.com/news/3493433-fanhua-reports-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3493433-fanhua-reports-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493425\" data-ts=\"1566333126\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TOL\" target=\"_blank\">TOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493425-toll-brothers-eps-beats-0_17-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toll Brothers EPS beats by $0.17, beats on revenue</a></h4><ul><li>Toll Brothers (NYSE:<a href='https://seekingalpha.com/symbol/TOL' title='Toll Brothers, Inc.'>TOL</a>): Q3 GAAP EPS of $1.00 <font color=\"green\">beats by $0.17</font>.</li><li>Revenue of $1.77B (-7.3% Y/Y) <font color=\"green\">beats by $70M</font>.</li><li>Shares <font color=\"green\">+4.04%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17608976-toll-brothers-reports-fy-2019-3rd-quarter-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3493425\" data-linked=\"Toll Brothers EPS beats by $0.17, beats on revenue\" data-tweet=\"$TOL - Toll Brothers EPS beats by $0.17, beats on revenue https://seekingalpha.com/news/3493425-toll-brothers-eps-beats-0_17-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3493425-toll-brothers-eps-beats-0_17-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493427\" data-ts=\"1566332635\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493427-la-z-boyplus-4-after-profit-topper\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">La-Z-Boy +4% after profit topper</a></h4><ul><li>La-Z-Boy (NYSE:<a href='https://seekingalpha.com/symbol/LZB' title='La-Z-Boy Incorporated'>LZB</a>) rallies after sailing past even the highest profit estimate turned in by analysts.</li><li>Written same-store sales for the La-Z-Boy Furniture Galleries network were up 4.7% during the quarter and same-store sales for the company-owned retail segment increased 3.5%.</li><li>The upholstery segment contributed $27.8M in operating income, while the casegoods business delivered $2.5M and retail OI was $8.5M.</li><li>CEO update: \"The home furnishings environment remains somewhat challenging amid tariff uncertainty and other geopolitical concerns. Against that backdrop, however, we continue to believe La-Z-Boy is competitively well positioned with a strong brand; multi-channel distribution, including a growing retail business; and a world-class supply chain, which we continue to work to optimize.\"</li><li>Shares of LZB are <font color=\"green\">up 3.88%</font> in AH trading to $31.83.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3493407-la-z-boy-eps-beats-0_08-misses-revenue\" target=\"_blank\">La-Z-Boy EPS beats by $0.08, misses on revenue</a> (Aug. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3493427\" data-linked=\"La-Z-Boy +4% after profit topper\" data-tweet=\"$LZB - La-Z-Boy +4% after profit topper https://seekingalpha.com/news/3493427-la-z-boyplus-4-after-profit-topper?source=tweet\" data-url=\"https://seekingalpha.com/news/3493427-la-z-boyplus-4-after-profit-topper\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493417\" data-ts=\"1566332602\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URBN\" target=\"_blank\">URBN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493417-urban-outfittersplus-4-after-positive-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Urban Outfitters +4% after positive outlook</a></h4><ul>  <li>Urban Outfitters (NASDAQ:<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a>) tracks higher after posting its <a href=\"https://seekingalpha.com/pr/17608922-urbn-reports-q2-results\" target=\"_blank\">Q2</a> report.</li>  <li>Comparable retail segment net sales fell 3% during the quarter, driven lower by soft store sales.</li>  <li>Comparable retail segment sales: Free People +6%, Urban Outfitters -5%, and Anthropologie Group -3%.</li>  <li>Wholesale segment net sales fell 8%.</li>  <li>Gross margin was 32.8% of sales vs. 32.9% consensus and 35.9% a year ago.</li> <li>SG&amp;A expenses as a percentage of sales deleveraged by 62 bps.</li><li>Comparable retail segment inventory increased 5% at cost during the quarter.</li><li>The look ahead from URBN management is positive. \"I am pleased to report that customer reaction to our early fall apparel assortments have improved significantly from our second quarter results,\" says CEO Richard Hayne. \"Third quarter-to-date \u2018comp' sales are positive at all three brands,\" he adds.</li>     <li>URBN <font color=\"green\">+3.87% </font>AH to $21.71.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3493399-urban-outfitters-eps-beats-0_03-misses-revenue\" target=\"_blank\">Urban Outfitters EPS beats by $0.03, misses on revenue</a> (Aug. 20)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3493417\" data-linked=\"Urban Outfitters +4% after positive outlook\" data-tweet=\"$URBN - Urban Outfitters +4% after positive outlook https://seekingalpha.com/news/3493417-urban-outfittersplus-4-after-positive-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3493417-urban-outfittersplus-4-after-positive-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493408\" data-ts=\"1566332300\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CREE\" target=\"_blank\">CREE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493408-creeminus-7_6-on-huawei-related-downside-view\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cree -7.6% on Huawei-related downside view</a></h4><ul><li>Cree (NASDAQ:<a href='https://seekingalpha.com/symbol/CREE' title='Cree, Inc.'>CREE</a>) <font color=\"red\">slides 7.6%</font> after <a href=\"https://seekingalpha.com/news/3493397-cree-eps-beats-0_01-beats-revenue\" target=\"_blank\">Q4 beats</a> with downside Q1 guidance that sees revenue of $237-243M (consensus: $259.24M) and loss per share of $0.07 to $0.03 (consensus: $0.15).</li><li>The company cites the short-term impact from the Huawei ban and softness in the LED market. The long-term outlook remains unchanged.</li><li>Q4 revenue: Wolfspeed, $134.2M (consensus: $133.7M); LED, $117M (consensus: $115.1M).</li><li>The gross margin was 37% versus the 36.2% consensus and 30% in last year's quarter. Operating margin was 4% versus the 5.2% estimate.</li><li>Earnings call starts at 5 PM with a webcast <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestor.cree.com%2Ffinancial-events-presentations&amp;esheet=52081781&amp;newsitemid=20190820005698&amp;lan=en-US&amp;anchor=investor.cree.com%2Fevents.cfm&amp;index=1&amp;md5=c8d1a5671d2756b059a088e3b83f0bf9\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17608903-cree-reports-financial-results-fourth-quarter-fiscal-year-2019\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493408\" data-linked=\"Cree -7.6% on Huawei-related downside view\" data-tweet=\"$CREE - Cree -7.6% on Huawei-related downside view https://seekingalpha.com/news/3493408-creeminus-7_6-on-huawei-related-downside-view?source=tweet\" data-url=\"https://seekingalpha.com/news/3493408-creeminus-7_6-on-huawei-related-downside-view\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493393\" data-ts=\"1566331007\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DOW\" target=\"_blank\">DOW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493393-dow-leads-chemical-names-lower-baml-sees-eroding-fundamentals\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dow leads chemical names lower as BAML sees &#39;eroding fundamentals&#39;</a></h4><ul><li>Dow Inc. (<a href='https://seekingalpha.com/symbol/DOW' title='Dow Inc.'>DOW</a> <font color='red'>-5.4%</font>) is one of today's two <a href=\"https://www.marketwatch.com/story/dows-stock-falls-to-lead-materials-peers-and-dow-industrials-losers-2019-08-20\" target=\"_blank\">biggest losers</a> on the S&amp;P 500, two trading sessions after BofA Merrill Lynch analyst Steve Byrne <a href=\"https://seekingalpha.com/news/3492575-dow-downgraded-sell-equivalent-bofa-merrill\" target=\"_blank\">slashed shares to Underperform</a> from Neutral with a $41 price target.</li><li>Byrne said Dow's success in controlling costs largely has been offset by \"eroding fundamentals\" across its polyethylene, methyl diphenyl diisocyanate, monoethylene glycol and Siloxanes products.</li><li>Other chemical names also trade lower: <a href='https://seekingalpha.com/symbol/LYB' title='LyondellBasell Industries N.V.'>LYB</a> <font color=\"red\">-2.9%</font>, <a href='https://seekingalpha.com/symbol/HUN' title='Huntsman Corporation'>HUN</a> <font color=\"red\">-2.2%</font>, <a href='https://seekingalpha.com/symbol/EMN' title='Eastman Chemical Company'>EMN</a> <font color=\"red\">-2.1%</font>, <a href='https://seekingalpha.com/symbol/WLK' title='Westlake Chemical Corporation'>WLK</a> <font color=\"red\">-1.6%</font>, <a href='https://seekingalpha.com/symbol/OLN' title='Olin Corporation'>OLN</a> <font color=\"red\">-1.6%</font>.</li><li>Separately, Dow announces <a href=\"https://seekingalpha.com/pr/17607939-dow-retrofit-louisiana-cracker-fluidized-catalytic-dehydrogenation-fcdh-technology-produce\" target=\"_blank\">plans to retrofit</a> its fluidized catalytic dehydrogenation technology into one of its mixed-feed crackers in Plaquemine, La., to produce on-purpose propylene.</li><li>Dow says the low-cost, high-return retrofit will enable the reliable supply of additional 100K-plus metric tons of propylene to meet growing demand across core end markets.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493393\" data-linked=\"Dow leads chemical names lower as BAML sees &#39;eroding fundamentals&#39;\" data-tweet=\"$DOW $LYB $HUN - Dow leads chemical names lower as BAML sees &#39;eroding fundamentals&#39; https://seekingalpha.com/news/3493393-dow-leads-chemical-names-lower-baml-sees-eroding-fundamentals?source=tweet\" data-url=\"https://seekingalpha.com/news/3493393-dow-leads-chemical-names-lower-baml-sees-eroding-fundamentals\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493389\" data-ts=\"1566330071\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCM\" target=\"_blank\">CMCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493389-cheetah-mobileplus-36-after-special-dividend-q2-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cheetah Mobile +36% after special dividend, Q2 earnings</a></h4><ul>   <li>Cheetah Mobile (NYSE:<a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a>) is <font color=\"green\">up 36.4%</font> today after posting <a href=\"https://seekingalpha.com/news/3493154-cheetah-mobile-reports-q2-results\" target=\"_blank\">Q2 results</a> and calling for a <a href=\"https://seekingalpha.com/news/3493151-cheetah-mobile-declares-0_50-dividend\" target=\"_blank\">special dividend of $0.50</a> per American Depositary Share.</li>    <li>Revenue dipped 12% but exceeded company guidance, driven by strength in mobile games and AI-related business. Cost of revenues fell 6.9%.</li>    <li>Gross profit dropped 14.5% to 643.3M yuan (about $93.7M).</li>    <li>With operating expenses up 12%, the company swung to an operating loss of 55.7M yuan from a year-ago gain of 127.9M yuan.</li>    <li>And attributable net income was 48.5M yuan (7.1M); non-GAAP net income was 82.5M yuan.</li>    <li>Revenue breakout: Utility products/related services, 423.5M yuan (down 44%); Mobile entertainment, 498M yuan (up 49.6%); AI and other, 48.6M yuan (up 236%).</li>    <li>Liquidity was 3.35B yuan ($488.2M) as of June 30.</li>    <li><a href=\"https://seekingalpha.com/article/4286863-cheetah-mobile-inc-cmcm-ceo-fu-sheng-q2-2019-results-earnings-call-transcript\" target=\"_blank\">Earnings call transcript</a></li>    <li><a href=\"https://seekingalpha.com/pr/17607868-cheetah-mobile-announces-second-quarter-2019-unaudited-consolidated-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3493389\" data-linked=\"Cheetah Mobile +36% after special dividend, Q2 earnings\" data-tweet=\"$CMCM - Cheetah Mobile +36% after special dividend, Q2 earnings https://seekingalpha.com/news/3493389-cheetah-mobileplus-36-after-special-dividend-q2-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3493389-cheetah-mobileplus-36-after-special-dividend-q2-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493385\" data-ts=\"1566328387\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TJX\" target=\"_blank\">TJX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493385-tjx-companies-sized-up-after-sales-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TJX Companies sized up after sales miss</a></h4><ul><li>Wolfe Research checks in on TJX Companies (<a href='https://seekingalpha.com/symbol/TJX' title='The TJX Companies, Inc.'>TJX</a> <font color='green'>+0.3%</font>) following the company's Q2 earnings report.</li><li>\"A disappointing 2Q19 was the antithesis of the upside and strength posted in 1Q. Sales and margins were negatively impacted by weather and product misses at Home Goods. In our opinion both of these are transitory and fixable,\" notes analyst Adrienne Yih.</li><li>Yih thinks with the rest of the front line apparel sector ailing, a strong partner and outlet may be needed to purge inventory. \"TJX has historically shown itself to be one of the first calls for brands looking to rid themselves of excess inventory; the opportunity keeps us sanguine entering 2H19 and looking ahead to 2020,\" she reasons.</li><li>Shares of TJX have bounced back from a <a href=\"https://seekingalpha.com/news/3493225-tjx-companies-minus-4-percent-comp-sales-disappoint\" target=\"_blank\">premarket dip</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493385\" data-linked=\"TJX Companies sized up after sales miss\" data-tweet=\"$TJX - TJX Companies sized up after sales miss https://seekingalpha.com/news/3493385-tjx-companies-sized-up-after-sales-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3493385-tjx-companies-sized-up-after-sales-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493381\" data-ts=\"1566327074\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493381-cang-oibr-c-se-and-vnet-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CANG, OIBR.C, SE and VNET among tech movers</a></h4><ul><li><strong>Gainers: </strong>SCWorx (NASDAQ:<a href='https://seekingalpha.com/symbol/WORX' title='SCWorx Corp.'>WORX</a>) <font color=\"green\">+45%</font>. Cheetah Mobile (NYSE:<a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a>) <font color=\"green\">+30%</font>. Foresight Autonomous Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/FRSX' title='Foresight Autonomous Holdings Ltd.'>FRSX</a>) <font color=\"green\">+24%</font>. Jiayin Group (NASDAQ:<a href='https://seekingalpha.com/symbol/JFIN' title='Jiayin Group Inc.'>JFIN</a>) <font color=\"green\">+11%</font>. 21Vianet Group (NASDAQ:<a href='https://seekingalpha.com/symbol/VNET' title='21Vianet Group, Inc.'>VNET</a>) <font color=\"green\">+11%</font>.</li> <li><strong>Losers: </strong>Oi S.A. (NYSE:<a href='https://seekingalpha.com/symbol/OIBR.C' title='Oi S.A.'>OIBR.C</a>) <font color=\"red\">-29%</font>. DPW Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a>) <font color=\"red\">-16%</font>. Cango (NYSE:<a href='https://seekingalpha.com/symbol/CANG' title='Cango Inc.'>CANG</a>) <font color=\"red\">-16%</font>. Aurora Mobile Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/JG' title='Aurora Mobile Limited'>JG</a>) <font color=\"red\">-10%</font>. Sea Limited (NYSE:<a href='https://seekingalpha.com/symbol/SE' title='Sea Limited'>SE</a>) <font color=\"red\">-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493381\" data-linked=\"CANG, OIBR.C, SE and VNET among tech movers\" data-tweet=\"$WORX $CMCM $FRSX - CANG, OIBR.C, SE and VNET among tech movers https://seekingalpha.com/news/3493381-cang-oibr-c-se-and-vnet-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3493381-cang-oibr-c-se-and-vnet-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493379\" data-ts=\"1566326710\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SJT\" target=\"_blank\">SJT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493379-no-august-cash-distribution-for-san-juan-basin-royalty-trust\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">No August cash distribution for San Juan Basin Royalty Trust</a></h4><ul><li>San Juan Basin Royalty Trust (<a href='https://seekingalpha.com/symbol/SJT' title='San Juan Basin Royalty Trust'>SJT</a> <font color='red'>-7.1%</font>) slides to within a few pennies of its 52-week low after its trustee confirmed the company <a href=\"https://seekingalpha.com/pr/17608283-san-juan-basin-royalty-trust-declares-cash-distribution-august-2019\" target=\"_blank\">will not pay a monthly cash distribution</a> for August, after June production costs and capital spending exceeded gross proceeds.</li><li>SJT says it does not expect to pay cash distributions in the future until gross proceeds can cover its liabilities and replenish its cash reserves after falling to below $785K on July 31.</li><li>The company says the excess production costs for the latest reporting period were due mostly to planned capital spending associated with the Fruitland Coal well drill and multiple well recompletions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493379\" data-linked=\"No August cash distribution for San Juan Basin Royalty Trust\" data-tweet=\"$SJT - No August cash distribution for San Juan Basin Royalty Trust https://seekingalpha.com/news/3493379-no-august-cash-distribution-for-san-juan-basin-royalty-trust?source=tweet\" data-url=\"https://seekingalpha.com/news/3493379-no-august-cash-distribution-for-san-juan-basin-royalty-trust\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493377\" data-ts=\"1566326108\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMY\" target=\"_blank\">HMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493377-harmony-gold-eyes-anglogold-mine-reserves-dwindle\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harmony Gold eyes AngloGold mine as reserves dwindle</a></h4><ul><li>Harmony Gold (<a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a> <font color='green'>+10%</font>) CEO Peter Steenkamp says the miner is <a href=\"https://www.mining.com/harmony-gold-mulls-anglogold-assets-acquisition-as-reserves-dwindle/\" target=\"_blank\">looking at acquiring new asset</a>s to sustain growth and replace capacity currently coming from its Masimong and Unisel mines in South Africa, which are running out of ore.</li><li>South Africa would remain HMY's primary investment target, Steenkamp said during a conference call today after issuing <a href=\"https://seekingalpha.com/news/3493196-harmony-gold-production-cash-flows-lifted-moab-khotsong-hidden-valley\" target=\"_blank\">full-year results</a>, revealing the Mponeng mine, AngloGold Ashanti's (<a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color='green'>+7.5%</font>) last underground operation in the country, was among the  many projects the company is considering.</li><li>Steenkamp also said HMY would delay and revise its planned work at its Papua New Guinea's Wafi-Golpu gold and copper project, where permitting has been stalled since May when the country elected a new prime minister.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493377\" data-linked=\"Harmony Gold eyes AngloGold mine as reserves dwindle\" data-tweet=\"$HMY $AU - Harmony Gold eyes AngloGold mine as reserves dwindle https://seekingalpha.com/news/3493377-harmony-gold-eyes-anglogold-mine-reserves-dwindle?source=tweet\" data-url=\"https://seekingalpha.com/news/3493377-harmony-gold-eyes-anglogold-mine-reserves-dwindle\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493374\" data-ts=\"1566325079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493374-ges-long-term-care-insurance-gets-thumbs-up-from-goldman-analysts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE&#39;s long-term care insurance gets thumbs-up from Goldman analysts</a></h4><ul><li>General Electric (<a href='https://seekingalpha.com/symbol/GE' title='General Electric Company'>GE</a> <font color='red'>-3.2%</font>) shares have been volatile since the publication of the critical report from whistleblower Harry Markopolos, which alleged the company employed fraudulent accounting in its long-term care insurance business, but a new Goldman Sachs analysis concludes GE's long-term care insurance reserves <a href=\"https://www.marketwatch.com/articles/goldman-sachs-gives-a-thumbs-up-to-ges-insurance-reserves-51566316293\" target=\"_blank\">appear to be \"rational.\"</a></li><li>Goldman industrial analyst Joe Ritchie and insurance analyst Alex Scott examined GE's life insurance reserves shortly after the release of the Markopolos report and said the company has higher reserves on a per-life basis than some peers, and today issued another report that took a deeper look at  the issue.</li><li>\"ERAC had the third highest reserves per life and UFLIC had the fifth largest reserves per life,\" according to Ritchie and Scott, referring to GE's two life insurance subsidiaries that hold legacy long-term care insurance policies.</li><li>\"We continue to view GE's block as having high reserves on a relative basis to peers with [about] $75,000 reserves per life compared with a peer average of [about] $31,000 and a median of [about] $26,000,\" Ritchie and Scott write, adding that the higher than average reserves appear \"rational\" given the nature of GE's long-term-care policies.</li><li>But shares remain lower today after Fitch Ratings said GE <a href=\"https://seekingalpha.com/news/3493296-ge-among-riskiest-long-term-care-insurers-fitch\" target=\"_blank\">ranks among the riskiest backers</a> of long-term care insurance, suffering from \"very high\" exposure to claims and a relatively small cash pile to pay them.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493374\" data-linked=\"GE&#39;s long-term care insurance gets thumbs-up from Goldman analysts\" data-tweet=\"$GE - GE&#39;s long-term care insurance gets thumbs-up from Goldman analysts https://seekingalpha.com/news/3493374-ges-long-term-care-insurance-gets-thumbs-up-from-goldman-analysts?source=tweet\" data-url=\"https://seekingalpha.com/news/3493374-ges-long-term-care-insurance-gets-thumbs-up-from-goldman-analysts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>69&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493371\" data-ts=\"1566324084\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493371-westwater-resources-and-synthesis-energy-systems-among-energy-materials-gainers-yuma-energy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Westwater Resources and Synthesis Energy Systems among Energy/Materials gainers; Yuma Energy and Seadrill Partners among losers</a></h4><ul><li><b>Gainers: </b>Westwater Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/WWR' title='Westwater Resources, Inc.'>WWR</a>) <font color=\"green\">+11%</font>. Synthesis Energy Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/SES' title='Synthesis Energy Systems, Inc.'>SES</a>) <font color=\"green\">+10%</font>. Gold Fields (NYSE:<a href='https://seekingalpha.com/symbol/GFI' title='Gold Fields Limited'>GFI</a>) <font color=\"green\">+9%</font>. Harmony Gold Mining (NYSE:<a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a>) <font color=\"green\">+8%</font>. AngloGold Ashanti (NYSE:<a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers: </b>Yuma Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a>) <font color=\"red\">-16%</font>. Seadrill Partners (NYSE:<a href='https://seekingalpha.com/symbol/SDLP' title='Seadrill Partners LLC'>SDLP</a>) <font color=\"red\">-10%</font>. Montage Resources (NYSE:<a href='https://seekingalpha.com/symbol/MR' title='Montage Resources Corporation'>MR</a>) <font color=\"red\">-8%</font>. Mammoth Energy Services (NASDAQ:<a href='https://seekingalpha.com/symbol/TUSK' title='Mammoth Energy Services, Inc.'>TUSK</a>) <font color=\"red\">-8%</font>. Range Resources (NYSE:<a href='https://seekingalpha.com/symbol/RRC' title='Range Resources Corporation'>RRC</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493371\" data-linked=\"Westwater Resources and Synthesis Energy Systems among Energy/Materials gainers; Yuma Energy and Seadrill Partners among losers\" data-tweet=\"$WWR $SES $GFI - Westwater Resources and Synthesis Energy Systems among Energy/Materials gainers; Yuma Energy and Seadrill Partners among losers https://seekingalpha.com/news/3493371-westwater-resources-and-synthesis-energy-systems-among-energy-materials-gainers-yuma-energy?source=tweet\" data-url=\"https://seekingalpha.com/news/3493371-westwater-resources-and-synthesis-energy-systems-among-energy-materials-gainers-yuma-energy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493364\" data-ts=\"1566322901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XLNX\" target=\"_blank\">XLNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493364-xilinx-soc-board-unpatchable-flaw-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xilinx SoC board has unpatchable flaw - report</a></h4><ul><li>Security researchers <a href=\"https://www.zdnet.com/article/unpatchable-security-flaw-found-in-popular-soc-boards/\" target=\"_blank\">have found</a> an unpatchable security flaw in the popular Xilinx (NASDAQ:<a href='https://seekingalpha.com/symbol/XLNX' title='Xilinx, Inc.'>XLNX</a>) Zynq UltraScale+ system-on-chip boards, which are used across a wide range of industries including auto, aviation, consumer electronics, and military applications.</li><li>F-Secure's hardware team Inverse Path found that the Encrypt Only secure boot mode contains two security flaws and doesn't encrypt boot image metadata, leaving the data vulnerable.</li><li>One flaw can't be fixed with a software update and will instead require a new silicon revision. Xilinx hasn't patched the other flaw because the unpatchable problem could let a hacker bypass the fix.</li><li>Xilinx statement: \"For systems that must use the Encrypt Only boot mode, customers are advised to consider system level protections that take into account DPA, unauthenticated boot, and partition header attack vectors.\"</li><li>Read the full technical report on GitHub.</li><li>Xilinx shares are <font color=\"red\">down 1.7%</font> to $105.08.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493364\" data-linked=\"Xilinx SoC board has unpatchable flaw - report\" data-tweet=\"$XLNX - Xilinx SoC board has unpatchable flaw - report https://seekingalpha.com/news/3493364-xilinx-soc-board-unpatchable-flaw-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3493364-xilinx-soc-board-unpatchable-flaw-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493363\" data-ts=\"1566322890\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493363-baron-capital-sticks-tesla\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baron Capital sticks with Tesla</a></h4><ul><li>Baron Capital hasn't sold any shares of Tesla (<a href='https://seekingalpha.com/symbol/TSLA' title='Tesla, Inc.'>TSLA</a> <font color='red'>-0.1%</font>) despite the \"self-inflicted wounds\" that have occurred at the company, according to CEO/CIO Ron Baron.</li><li>The longtime Tesla proponent still sees an opportunity for a share price rally as EV battery costs come down and the business in China expands.</li><li>Baron Capital holds more than 1.6M shares of Tesla with an estimated cost basis of around $218.</li><li><a href=\"https://www.cnbc.com/2019/08/20/tesla-investor-baron-still-believes-in-musk-despite-self-inflicted-wounds.html\" target=\"_blank\">CNBC interview</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3493363\" data-linked=\"Baron Capital sticks with Tesla\" data-tweet=\"$TSLA - Baron Capital sticks with Tesla https://seekingalpha.com/news/3493363-baron-capital-sticks-tesla?source=tweet\" data-url=\"https://seekingalpha.com/news/3493363-baron-capital-sticks-tesla\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>116&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493360\" data-ts=\"1566321966\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493360-atlanticus-holdings-leads-financial-gainers-no-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Atlanticus Holdings leads financial gainers, with no losers</a></h4><ul><li><b>Gainers:</b> Atlanticus Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/ATLC' title='Atlanticus Holdings Corporation'>ATLC</a>) <font color=\"green\">+13%</font>. Jupai Holdings (NYSE:<a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings Limited'>JP</a>) <font color=\"green\">+9%</font>. EverQuote (NASDAQ:<a href='https://seekingalpha.com/symbol/EVER' title='EverQuote, Inc.'>EVER</a>) <font color=\"green\">+8%</font>. China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"green\">+6%</font>. Impac Mortgage Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/IMH' title='Impac Mortgage Holdings, Inc.'>IMH</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> None</li></ul><div class=\"tiny-share-widget\" data-id=\"3493360\" data-linked=\"Atlanticus Holdings leads financial gainers, with no losers\" data-tweet=\"$ATLC $JP $EVER - Atlanticus Holdings leads financial gainers, with no losers https://seekingalpha.com/news/3493360-atlanticus-holdings-leads-financial-gainers-no-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3493360-atlanticus-holdings-leads-financial-gainers-no-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493356\" data-ts=\"1566321032\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KSS\" target=\"_blank\">KSS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493356-kohls-bid-down-on-gross-margin-worries\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kohl&#39;s bid down on gross margin worries</a></h4><ul> <li>Shares of Kohl's (<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a> <font color='red'>-5.6%</font>) have reversed since an initial premarket post-earnings gain.</li> <li>Investors are said to be lasering in on the drop in gross margin guidance by the department store operator. Kohl's <a href=\"https://www.reuters.com/article/us-kohls-results/kohls-cuts-2019-margin-forecaston-tariffs-first-half-promotions-cost-idUSKCN1VA12P?feedType=RSS&amp;feedName=businessNews\" target=\"_blank\">expects</a> gross margins to be fall 35 basis points to 45 basis points vs. a prior forecast for a 20 bps to 30 bps decline.</li> <li>While Kohl's has the Amazon returns program working in its favor, it's facing some of the same tariff headwinds of the rest of the apparel sector.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3493152-kohls-eps-beats-0_02-beats-revenue\" target=\"_blank\">Kohl's EPS beats by $0.02, beats on revenue</a> (Aug. 20)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3493159-kohls-plus-4-percent-profit-beat\" target=\"_blank\">Kohl's +4% after profit beat</a> (Aug. 20)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493356\" data-linked=\"Kohl&#39;s bid down on gross margin worries\" data-tweet=\"$KSS - Kohl&#39;s bid down on gross margin worries https://seekingalpha.com/news/3493356-kohls-bid-down-on-gross-margin-worries?source=tweet\" data-url=\"https://seekingalpha.com/news/3493356-kohls-bid-down-on-gross-margin-worries\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493353\" data-ts=\"1566320488\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493353-cemtrex-leads-industrial-gainers-briggs-stratton-and-dmc-global-in-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cemtrex leads industrial gainers; Briggs &amp; Stratton and DMC Global in losers</a></h4><ul><li><b>Gainers: </b>Cemtrex (NASDAQ:<a href='https://seekingalpha.com/symbol/CETX' title='Cemtrex, Inc.'>CETX</a>) <font color=\"green\">+89%</font>. RADA Electronic Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/RADA' title='RADA Electronic Industries Ltd.'>RADA</a>) <font color=\"green\">+14%</font>. U.S. Well Services (NASDAQ:<a href='https://seekingalpha.com/symbol/USWS' title='U.S. Well Services, Inc.'>USWS</a>) <font color=\"green\">+13%</font>. Ocean Power Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/OPTT' title='Ocean Power Technologies, Inc.'>OPTT</a>) <font color=\"green\">+9% </font>Industrial Services of America (NASDAQ:<a href='https://seekingalpha.com/symbol/IDSA' title='Industrial Services of America, Inc.'>IDSA</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Briggs &amp; Stratton (NYSE:<a href='https://seekingalpha.com/symbol/BGG' title='Briggs & Stratton Corporation'>BGG</a>) <font color=\"red\">-9%</font>. DMC Global (NASDAQ:<a href='https://seekingalpha.com/symbol/BOOM' title='DMC Global Inc.'>BOOM</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493353\" data-linked=\"Cemtrex leads industrial gainers; Briggs &amp; Stratton and DMC Global in losers\" data-tweet=\"$CETX $RADA $USWS - Cemtrex leads industrial gainers; Briggs &amp; Stratton and DMC Global in losers https://seekingalpha.com/news/3493353-cemtrex-leads-industrial-gainers-briggs-stratton-and-dmc-global-in-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3493353-cemtrex-leads-industrial-gainers-briggs-stratton-and-dmc-global-in-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493348\" data-ts=\"1566319454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WORX\" target=\"_blank\">WORX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493348-scworx-up-26-ahead-of-business-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SCWorx up 26% ahead of business update</a></h4><ul><li>Thinly traded nano cap SCWorx (<a href='https://seekingalpha.com/symbol/WORX' title='SCWorx Corp.'>WORX</a> <font color=\"green\">+25.6%</font>) is up on almost a 4x surge in volume, albeit on turnover of only 129K shares, ahead of Thursday's <a href=\"https://seekingalpha.com/pr/17608060-scworx-provide-shareholders-corporate-update-august-22-2019\" target=\"_blank\">corporate update</a> at 4:30 pm ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493348\" data-linked=\"SCWorx up 26% ahead of business update\" data-tweet=\"$WORX - SCWorx up 26% ahead of business update https://seekingalpha.com/news/3493348-scworx-up-26-ahead-of-business-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3493348-scworx-up-26-ahead-of-business-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493345\" data-ts=\"1566318993\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493345-microcaps-mostly-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps mostly among midday movers</a></h4><ul><li><strong>Gainers</strong>: Cemtrex (NASDAQ:<a href='https://seekingalpha.com/symbol/CETX' title='Cemtrex, Inc.'>CETX</a>) <font color=\"green\">+91%</font>. SCWorx (NASDAQ:<a href='https://seekingalpha.com/symbol/WORX' title='SCWorx Corp.'>WORX</a>) <font color=\"green\">+30%</font>. Cheetah Mobile (NYSE:<a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a>) <font color=\"green\">+27%</font>. Endo International (NASDAQ:<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a>) <font color=\"green\">+26%</font>. MOGU (NYSE:<a href='https://seekingalpha.com/symbol/MOGU' title='MOGU Inc.'>MOGU</a>) <font color=\"green\">+18%</font>. VIVUS (NASDAQ:<a href='https://seekingalpha.com/symbol/VVUS' title='VIVUS, Inc.'>VVUS</a>) <font color=\"green\">+17%</font>. Mereo BioPharma Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MREO' title='Mereo BioPharma Group plc'>MREO</a>) <font color=\"green\">+16%</font>. Foresight Autonomous Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/FRSX' title='Foresight Autonomous Holdings Ltd.'>FRSX</a>) <font color=\"green\">+14%</font>. Atlanticus Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/ATLC' title='Atlanticus Holdings Corporation'>ATLC</a>) <font color=\"green\">+15%</font>. PhaseBio Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PHAS' title='PhaseBio Pharmaceuticals, Inc.'>PHAS</a>) <font color=\"green\">+13%</font>.</li> <li><strong>Losers</strong>: Synlogic (NASDAQ:<a href='https://seekingalpha.com/symbol/SYBX' title='Synlogic, Inc.'>SYBX</a>) <font color=\"red\">-29%</font>. Oi S.A. (OIBR-C) <font color=\"red\">-21%</font>. Yuma Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a>) <font color=\"red\">-16%</font>. Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) <font color=\"red\">-16%</font>. Trinity Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/TRIB' title='Trinity Biotech plc'>TRIB</a>) <font color=\"red\">-16%</font>. Fabrinet (NYSE:<a href='https://seekingalpha.com/symbol/FN' title='Fabrinet'>FN</a>) <font color=\"red\">-16%</font>. DPW Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a>) <font color=\"red\">-13%</font>. Assertio Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ASRT' title='Assertio Therapeutics, Inc.'>ASRT</a>) <font color=\"red\">-15%</font>. Trans World Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/TWMC' title='Trans World Entertainment Corporation'>TWMC</a>) <font color=\"red\">-14%</font>. Organogenesis Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/ORGO' title='Organogenesis Holdings Inc.'>ORGO</a>) <font color=\"red\">-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493345\" data-linked=\"Microcaps mostly among midday movers\" data-tweet=\"$CETX $WORX $CMCM - Microcaps mostly among midday movers https://seekingalpha.com/news/3493345-microcaps-mostly-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3493345-microcaps-mostly-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493336\" data-ts=\"1566318227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TACO\" target=\"_blank\">TACO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493336-del-taco-rallies-on-report-on-sale-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Del Taco rallies on report on sale talk</a></h4><ul> <li>Del Taco (<a href='https://seekingalpha.com/symbol/TACO' title='Del Taco Restaurants, Inc.'>TACO</a> <font color='green'>+4.9%</font>) moves higher after StreetInsider <a href=\"https://www.streetinsider.com/Hot+M+and+A/Del+Taco+%28TACO%29+Said+to+Mull+Sale+-+Source/15837210.html\" target=\"_blank\">reports</a> the restaurant is considering a sale.</li> <li>Sources indicate that the company has hired bankers to help it with the process.</li> <li>M&amp;A activity has picked up in the restaurant sector in general, with most of the interest coming from private equity firms.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493336\" data-linked=\"Del Taco rallies on report on sale talk\" data-tweet=\"$TACO - Del Taco rallies on report on sale talk https://seekingalpha.com/news/3493336-del-taco-rallies-on-report-on-sale-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3493336-del-taco-rallies-on-report-on-sale-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493334\" data-ts=\"1566317977\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TBGNF\" target=\"_blank\">TBGNF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493334-oxurions-thrminus-317-flunks-mid-stage-dme-study-shares-down-31\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oxurion&#39;s THR-317 flunks mid-stage DME study, shares down 31%</a></h4><ul><li>Ultra-thinly traded micro cap Oxurion NV (<a href='https://seekingalpha.com/symbol/TBGNF' title='Oxurion NV'>OTCPK:TBGNF</a> <font color=\"red\">-30.8%</font>) is down on double normal volume, a scant 1,500 shares, following its <a href=\"https://seekingalpha.com/pr/17607666-oxurion-nv-reports-topline-month-3-results-phase-2a-study-evaluating-thrminus-317-anti-plgf\" target=\"_blank\">announcement </a>of topline results from a proof-of-concept <a href=\"https://clinicaltrials.gov/ct2/show/NCT03499223?term=NCT03499223&amp;rank=1\" target=\"_blank\">Phase 2a clinical trial</a> evaluating THR-317, combined with Roche's Lucentis (ranibizumab), in patients with diabetic macular edema &#40;DME&#41;.</li><li>At month 3, no improvement in average Best Corrected Visual Acuity &#40;BCVA&#41; was observed in the combo arm in the overall population compared to control (ranibizumab + sham). There was an improvement in two subgroups: patients with poor or no response to prior anti-VEGF therapy (e.g., Lucentis) and those with baseline BCVA of no more than 65 letters.</li><li>No significant safety signals were observed.</li><li>THR-317 is a humanized monoclonal antibody that inhibits (binds to) a protein called <a href=\"https://www.sciencedirect.com/topics/neuroscience/placental-growth-factor\" target=\"_blank\">placental growth factor</a> which is a member of the VEGF family. It plays a key role in regulating vascular function.</li><li><a href=\"https://www.vsp.com/eyewear-wellness/eye-health/diabetic-macular-edema\" target=\"_blank\">DME </a>is characterized by the accumulation of fluid leaking from blood vessels in part of the retina called the macula which controls detailed vision.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493334\" data-linked=\"Oxurion&#39;s THR-317 flunks mid-stage DME study, shares down 31%\" data-tweet=\"$TBGNF - Oxurion&#39;s THR-317 flunks mid-stage DME study, shares down 31% https://seekingalpha.com/news/3493334-oxurions-thrminus-317-flunks-mid-stage-dme-study-shares-down-31?source=tweet\" data-url=\"https://seekingalpha.com/news/3493334-oxurions-thrminus-317-flunks-mid-stage-dme-study-shares-down-31\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493333\" data-ts=\"1566317379\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCO\" target=\"_blank\">CCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493333-clear-channel-outdoorplus-6_7-on-insider-buys\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clear Channel Outdoor +6.7% on more insider buys</a></h4><ul>   <li>Clear Channel Outdoor Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CCO' title='Clear Channel Outdoor Holdings, Inc.'>CCO</a>) is moving again on insider purchases, <font color=\"green\">up 6.7%</font> today.</li>    <li>Chief Financial Officer Brian Coleman disclosed <a href=\"https://seekingalpha.com/filing/4608802\" target=\"_blank\">purchasing 25,000 more shares</a> at an average price of $2.3025 (total of $57,562.50). That puts his beneficial ownership at 164,727 shares.</li>    <li>Also, director Andrew Hobson <a href=\"https://seekingalpha.com/filing/4608806\" target=\"_blank\">purchased 200,000 shares</a> at $2.3168 (about $463,360 worth). That sets his ownership at 241,840 shares.</li>    <li>Shares had <font color=\"green\">gained 10.7%</font> yesterday after <a href=\"https://seekingalpha.com/news/3492737-clear-channel-outdoor-plus-7_1-percent-amid-insider-buying\" target=\"_blank\">late Friday disclosures of purchases</a> by Coleman, Chairman Benjamin Moreland and Americas CEO Scott Wells.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493333\" data-linked=\"Clear Channel Outdoor +6.7% on more insider buys\" data-tweet=\"$CCO - Clear Channel Outdoor +6.7% on more insider buys https://seekingalpha.com/news/3493333-clear-channel-outdoorplus-6_7-on-insider-buys?source=tweet\" data-url=\"https://seekingalpha.com/news/3493333-clear-channel-outdoorplus-6_7-on-insider-buys\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493329\" data-ts=\"1566316835\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493329-beyond-meat-leads-consumer-gainers-fabrinet-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Beyond Meat leads consumer gainers; Fabrinet leads the losers</a></h4><ul><li><b>Gainers: </b>Beyond Meat (NASDAQ:<a href='https://seekingalpha.com/symbol/BYND' title='Beyond Meat, Inc.'>BYND</a>) <font color=\"green\">+7%</font>. Niu Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/NIU' title='Niu Technologies'>NIU</a>) <font color=\"green\">+7%</font>. Pilgrim's Pride (NASDAQ:<a href='https://seekingalpha.com/symbol/PPC' title='Pilgrim&#39;s Pride Corporation'>PPC</a>) <font color=\"green\">+6%</font>. Purple Innovation (NASDAQ:<a href='https://seekingalpha.com/symbol/PRPL' title='Purple Innovation, Inc.'>PRPL</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Fabrinet (NYSE:<a href='https://seekingalpha.com/symbol/FN' title='Fabrinet'>FN</a>) <font color=\"red\">-16%</font>. American Axle &amp; Manufacturing (NYSE:<a href='https://seekingalpha.com/symbol/AXL' title='American Axle & Manufacturing Holdings, Inc.'>AXL</a>) <font color=\"red\">-6%</font>. e.l.f. Beauty (NYSE:<a href='https://seekingalpha.com/symbol/ELF' title='e.l.f. Beauty, Inc.'>ELF</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493329\" data-linked=\"Beyond Meat leads consumer gainers; Fabrinet leads the losers\" data-tweet=\"$BYND $NIU $PPC - Beyond Meat leads consumer gainers; Fabrinet leads the losers https://seekingalpha.com/news/3493329-beyond-meat-leads-consumer-gainers-fabrinet-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3493329-beyond-meat-leads-consumer-gainers-fabrinet-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493325\" data-ts=\"1566316359\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VUZI\" target=\"_blank\">VUZI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493325-vuzix-receives-follow-on-smart-glasses-order\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vuzix receives follow-on smart glasses order</a></h4><ul><li>Vuzix (<a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corporation'>VUZI</a> <font color='red'>-2.8%</font>) <a href=\"https://seekingalpha.com/pr/17608669-vuzix-receives-follow-smart-glasses-order-1minuut-innovation-healthcare-industry-deployments\" target=\"_blank\">announces</a> the order from Dutch medical services company 1Minuut Innovation for over 100 M-series systems with plans to transition to the M400.</li><li>Financial terms weren't disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493325\" data-linked=\"Vuzix receives follow-on smart glasses order\" data-tweet=\"$VUZI - Vuzix receives follow-on smart glasses order https://seekingalpha.com/news/3493325-vuzix-receives-follow-on-smart-glasses-order?source=tweet\" data-url=\"https://seekingalpha.com/news/3493325-vuzix-receives-follow-on-smart-glasses-order\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493316\" data-ts=\"1566314670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493316-investors-skittish-on-airline-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors skittish on airline stocks</a></h4><ul> <li>The global airline sector remains under pressure due to persistent concerns about economic activity and trade war repercussions.</li> <li>Despite the investor concerns, global load factor has been fairly impressive this year, including a record for June of 84.4% per <a href=\"https://www.iata.org/pressroom/pr/Pages/2019-08-08-01.aspx\" target=\"_blank\">IATA data</a>.</li> <li>Decliners today include Avianca Holdings (NYSE:<a href='https://seekingalpha.com/symbol/AVH' title='Avianca Holdings S.A.'>AVH</a>)<font color=\"red\"> -7.1%,</font> Mesa Airlines (NASDAQ:<a href='https://seekingalpha.com/symbol/MESA' title='Mesa Air Group, Inc.'>MESA</a>) <font color=\"red\">-2.8%</font>, Deutsche Lufthansa (<a href='https://seekingalpha.com/symbol/DLAKF' title='Deutsche Lufthansa AG'>OTCQX:DLAKF</a>) <font color=\"red\">-5.5%</font> in Frankfurt, China Southern Airlines (NYSE:<a href='https://seekingalpha.com/symbol/ZNH' title='China Southern Airlines Company Limited'>ZNH</a>) <font color=\"red\">-2.8%</font>, China Eastern Airlines (NYSE:<a href='https://seekingalpha.com/symbol/CEA' title='China Eastern Airlines Corporation Limited'>CEA</a>) <font color=\"red\">-2.6%</font>, Ryanair (NASDAQ:<a href='https://seekingalpha.com/symbol/RYAAY' title='Ryanair Holdings plc'>RYAAY</a>) <font color=\"red\">-2.0%</font>, Alaska Air Group (NYSE:<a href='https://seekingalpha.com/symbol/ALK' title='Alaska Air Group, Inc.'>ALK</a>) <font color=\"red\">-1.5%</font>, SkyWest (NASDAQ:<a href='https://seekingalpha.com/symbol/SKYW' title='SkyWest, Inc.'>SKYW</a>) <font color=\"red\">-1.2%</font>, Southwest Airlines (NYSE:<a href='https://seekingalpha.com/symbol/LUV' title='Southwest Airlines Co.'>LUV</a>) <font color=\"red\">-1.1%</font>, EasyJet (<a href='https://seekingalpha.com/symbol/EJTTF' title='easyJet plc'>OTCPK:EJTTF</a>) <font color=\"red\">-1.0%</font> in London and American Airlines Group (NASDAQ:<a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group Inc.'>AAL</a>) <font color=\"red\">-1.0%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493316\" data-linked=\"Investors skittish on airline stocks\" data-tweet=\"$AVH $MESA $DLAKF - Investors skittish on airline stocks https://seekingalpha.com/news/3493316-investors-skittish-on-airline-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3493316-investors-skittish-on-airline-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493315\" data-ts=\"1566314113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OTLK\" target=\"_blank\">OTLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493315-outlook-hits-enrollment-target-in-late-stage-study-of-onsminus-5010-in-wetamd\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Outlook hits enrollment target in late-stage study of ONS-5010 in wetAMD</a></h4><ul><li>Outlook Therapeutics (<a href='https://seekingalpha.com/symbol/OTLK' title='Outlook Therapeutics, Inc.'>OTLK</a> <font color=\"green\">+1%</font>) <a href=\"https://seekingalpha.com/pr/17608059-outlook-therapeutics-completes-patient-enrollment-norse-1-phase-3-clinical-trial-onsminus\" target=\"_blank\">completes enrollment</a> in its Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT03844074?lead=outlook+therapeutics&amp;phase=2&amp;rank=1\" target=\"_blank\">NORSE 1</a> study evaluating ONS-5010 in patients with wet age-related macular degeneration (wet AMD) and other retinal disease.</li><li>61 subjects have been recruited across nine sites in Australia. The primary endpoint is the mean change from baseline in visual acuity at month 11 compared to Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding AG'>OTCQX:RHHBY</a> <font color=\"red\">-0.3%</font>) Lucentis (ranibizumab). Topline data should be available in Q3 2020.</li><li>If successful, the company plans to file marketing applications in multiple markets in late 2020.</li><li>ONS-5010 is an ophthalmic formulation of Roche's colorectal cancer med Avastin (bevacizumab) that is administered via intravitreal injection. Off-label Avastin accounts for about half or more of U.S. prescriptions for wetAMD.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493315\" data-linked=\"Outlook hits enrollment target in late-stage study of ONS-5010 in wetAMD\" data-tweet=\"$OTLK $RHHBY - Outlook hits enrollment target in late-stage study of ONS-5010 in wetAMD https://seekingalpha.com/news/3493315-outlook-hits-enrollment-target-in-late-stage-study-of-onsminus-5010-in-wetamd?source=tweet\" data-url=\"https://seekingalpha.com/news/3493315-outlook-hits-enrollment-target-in-late-stage-study-of-onsminus-5010-in-wetamd\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493307\" data-ts=\"1566313336\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493307-netflix-loses-300-handle-on-apple-tv-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Netflix loses $300 handle on Apple TV+ news</a></h4><ul> <li>Netflix (NASDAQ:<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a>) falls on some selling pressure that appears to be related to news that Apple is rolling out its Apple TV+ service by November, the same month that Disney+ is anticipated to debut.</li> <li>Shares of Netflix are <font color=\"red\">down 3.09%</font> to $299.83 vs. the 52-week trading range of $231.23 to $386.80.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3493307\" data-linked=\"Netflix loses $300 handle on Apple TV+ news\" data-tweet=\"$NFLX - Netflix loses $300 handle on Apple TV+ news https://seekingalpha.com/news/3493307-netflix-loses-300-handle-on-apple-tv-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3493307-netflix-loses-300-handle-on-apple-tv-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>68&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493305\" data-ts=\"1566313310\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493305-endo-international-leads-healthcare-gainers-sarepta-therapeutics-and-trovagene-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endo International leads healthcare gainers; Sarepta Therapeutics and TrovaGene among losers</a></h4><ul><li><b>Gainers: </b>Endo International (NASDAQ:<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a>) <font color=\"green\">+27%</font>. VIVUS (NASDAQ:<a href='https://seekingalpha.com/symbol/VVUS' title='VIVUS, Inc.'>VVUS</a>) <font color=\"green\">+21%</font>. Soliton (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLY' title='Soliton, Inc.'>SOLY</a>) <font color=\"green\">+16%</font>. InspireMD (NYSEMKT:<a href='https://seekingalpha.com/symbol/NSPR' title='InspireMD, Inc.'>NSPR</a>) <font color=\"green\">+14%</font>. Ardelyx (NASDAQ:<a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx, Inc.'>ARDX</a>) <font color=\"green\">+11%</font>.</li><li><b>Losers: </b>Synlogic (NASDAQ:<a href='https://seekingalpha.com/symbol/SYBX' title='Synlogic, Inc.'>SYBX</a>) <font color=\"red\">-30%</font>. NuCana (NASDAQ:<a href='https://seekingalpha.com/symbol/NCNA' title='NuCana plc'>NCNA</a>) <font color=\"red\">-20%</font>. Assertio Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ASRT' title='Assertio Therapeutics, Inc.'>ASRT</a>) <font color=\"red\">-14%</font>. Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) <font color=\"red\">-14%</font>. TrovaGene (NASDAQ:<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>) <font color=\"red\">-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493305\" data-linked=\"Endo International leads healthcare gainers; Sarepta Therapeutics and TrovaGene among losers\" data-tweet=\"$ENDP $VVUS $SOLY - Endo International leads healthcare gainers; Sarepta Therapeutics and TrovaGene among losers https://seekingalpha.com/news/3493305-endo-international-leads-healthcare-gainers-sarepta-therapeutics-and-trovagene-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3493305-endo-international-leads-healthcare-gainers-sarepta-therapeutics-and-trovagene-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493295\" data-ts=\"1566312132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSG\" target=\"_blank\">MSG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493295-msgminus-8-q4-builds-on-losses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MSG -8% as Q4 builds on losses</a></h4><ul>   <li>Madison Square Garden (NYSE:<a href='https://seekingalpha.com/symbol/MSG' title='The Madison Square Garden Company'>MSG</a>) is down sharply in early trading, <font color=\"red\">-8%</font>, after missing in <a href=\"https://seekingalpha.com/news/3493157-madison-square-garden-eps-misses-0_57-misses-revenue\" target=\"_blank\">fiscal Q4 earnings</a> with a double-digit drop in revenues and wider operating losses.</li>    <li>While revenues grew for the fiscal year, they dropped 17% in Q4 to $263.6M; results were affected in part by a July 1, 2018, adoption of ASC Topic 606 for revenue recognition.</li>    <li>Excluding that impact, Q4 revenues would have been $326.2M (a 3% gain).</li>    <li>Operating loss swelled to $79.9M vs. a prior-year loss of $44.2M; adjusted operating loss increased to $34.9M vs. a year-ago loss of $1.3M.</li>    <li>Revenue by segment: MSG Entertainment, $174M (down 6%); MSG Sports, $90M (down 32%).</li>    <li>MSG Entertainment saw lower event-related revenues at venues and at the Boston Calling festival. In sports, the company was particularly hit by the impact of ASC 606, with  a heavy effect on ticket-related revenue, media rights fees from MSG Networks, suite license fees, league distributions and sponsorship/signage revenues.</li>    <li><a href=\"https://seekingalpha.com/pr/17607889-madison-square-garden-company-reports-fourth-quarter-fiscal-2019-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3493295\" data-linked=\"MSG -8% as Q4 builds on losses\" data-tweet=\"$MSG - MSG -8% as Q4 builds on losses https://seekingalpha.com/news/3493295-msgminus-8-q4-builds-on-losses?source=tweet\" data-url=\"https://seekingalpha.com/news/3493295-msgminus-8-q4-builds-on-losses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493291\" data-ts=\"1566311577\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493291-tuanche-rallies-13-post-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TuanChe rallies 13% post Q2 results</a></h4><ul><li>TuanChe (<a href='https://seekingalpha.com/symbol/TC' title='TuanChe Limited'>TC</a> <font color=\"green\">+13%</font>) reports <a href=\"https://seekingalpha.com/pr/17607785-tuanche-announces-unaudited-second-quarter-2019-financial-results\" target=\"_blank\">Q2</a> revenue growth of 11.9% Y/Y to RMB203.5M.</li><li>Gross margin <font color=\"red\">declined 180 bps</font> to 70.8%.</li><li>Adj. EBITDA was a loss of RMB30.4M compared to an income of RMB17.7M Y/Y.</li><li>Quarterly number of auto shows organized increased by 57.1% Y/Y to 344 auto shows in 186 cities from 219 auto shows in 116 cities across China.</li><li>Quarterly number of automobile sales transactions facilitated increased by 12% Y/Y to 110,444 and the quarterly Gross Merchandise Volume of new automobiles sold increased by 7.8% Y/Y to RMB15.2B.</li><li>Geographic coverage of sales operations sites further expanded to 155 cities (+28.1% Y/Y).</li><li>The Company had cash and equivalents of RMB364.3M and net cash used in operating activities was RMB7.7M.</li><li><b>Q3 Outlook:</b> The Company expects net revenues from ~RMB160-170M, representing an ~Y/Y growth of 3%-9.5%.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3493132-tuanche-eps-misses-0_02-misses-revenue\" target=\"_blank\">TuanChe EPS misses by $0.02, misses on revenue</a> (Aug. 20 2019)</li></ul><div class=\"tiny-share-widget\" data-id=\"3493291\" data-linked=\"TuanChe rallies 13% post Q2 results\" data-tweet=\"$TC - TuanChe rallies 13% post Q2 results https://seekingalpha.com/news/3493291-tuanche-rallies-13-post-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3493291-tuanche-rallies-13-post-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493289\" data-ts=\"1566311330\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TXMD\" target=\"_blank\">TXMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493289-sec-charges-therapeuticsmd-reg-fd-violations-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SEC charges TherapeuticsMD with Reg FD violations; shares down 4%</a></h4><ul><li>The SEC has charged TherapeuticsMD (<a href='https://seekingalpha.com/symbol/TXMD' title='TherapeuticsMD, Inc.'>TXMD</a> <font color=\"red\">-3.5%</font>) will <a href=\"https://www.sec.gov/news/press-release/2019-156\" target=\"_blank\">violating</a> Regulation Fair Disclosure &#40;FD&#41; by sharing material nonpublic information with sell-side analysts without disclosing the same information to the public.</li><li>The alleged violations occurred in June and July 2017 and were related to tipping analysts about its interactions with the FDA pertaining to a new product approval.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493289\" data-linked=\"SEC charges TherapeuticsMD with Reg FD violations; shares down 4%\" data-tweet=\"$TXMD - SEC charges TherapeuticsMD with Reg FD violations; shares down 4% https://seekingalpha.com/news/3493289-sec-charges-therapeuticsmd-reg-fd-violations-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3493289-sec-charges-therapeuticsmd-reg-fd-violations-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493288\" data-ts=\"1566311236\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MORL\" target=\"_blank\">MORL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493288-volatility-ahead-for-mreits-in-q3-nomura-instinet-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More volatility ahead for mREITs in Q3, Nomura Instinet says</a></h4><ul><li>Nomura Instinet analyst Matthew Howlett writes, since mREIT Q2 earnings season ended, \"volatility has increased substantially with mortgage spreads widening to levels not seen since the '10-'11 period.\"</li><li>Estimates that the 1.7%-3.5% gains in mREIT book values reported in July are likely wiped out in August, depending on hedging and asset selection, he adds.</li><li>Prepayments continue to rise sharply and Q3 is \"poised to have high speeds for all three months in the quarter.\"</li><li>ETFs: <a href='https://seekingalpha.com/symbol/MORL' title='UBS ETRACS Monthly Pay 2x Leveraged Mortgage REIT ETN'>MORL</a>, <a href='https://seekingalpha.com/symbol/REM' title='iShares Mortgage Real Estate Capped ETF'>REM</a>, <a href='https://seekingalpha.com/symbol/MORT' title='VanEck Vectors Mortgage REIT Income ETF'>MORT</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3493288\" data-linked=\"More volatility ahead for mREITs in Q3, Nomura Instinet says\" data-tweet=\"$MORL $REM $MORT - More volatility ahead for mREITs in Q3, Nomura Instinet says https://seekingalpha.com/news/3493288-volatility-ahead-for-mreits-in-q3-nomura-instinet-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3493288-volatility-ahead-for-mreits-in-q3-nomura-instinet-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493285\" data-ts=\"1566310785\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASGN\" target=\"_blank\">ASGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493285-asgn-division-recieves-us-marine-corps-m-sharp-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ASGN division recieves US Marine Corps M-SHARP contract</a></h4><ul><li>ASGN (<a href='https://seekingalpha.com/symbol/ASGN' title='ASGN Incorporated'>ASGN</a> <font color=\"red\">-0.1%</font>) division ECS has been <a href=\"https://seekingalpha.com/pr/17608427-ecs-awarded-us-marine-corps-m-sharp-contract\" target=\"_blank\">awarded</a> a three-year, firm-fixed-price, $19M contract to support the Marine Sierra Hotel Aviation Readiness Program (M-SHARP).</li><li>M-SHARP is a web-based training management program that supports all Marine Aviation Operational and Headquarters units with real-time forecasting, scheduling, execution, and reporting to achieve and maintain combat readiness.</li><li>ECS will implement new and enhanced functionality to M-SHARP, enabling more simulator and ground-unit utilization.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493285\" data-linked=\"ASGN division recieves US Marine Corps M-SHARP contract\" data-tweet=\"$ASGN - ASGN division recieves US Marine Corps M-SHARP contract https://seekingalpha.com/news/3493285-asgn-division-recieves-us-marine-corps-m-sharp-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3493285-asgn-division-recieves-us-marine-corps-m-sharp-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493283\" data-ts=\"1566310659\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SOLY\" target=\"_blank\">SOLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493283-soliton-up-18-on-encouraging-data-supporting-longer-rap-treatment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Soliton up 18% on encouraging data supporting longer RAP treatment</a></h4><ul><li>Soliton (<a href='https://seekingalpha.com/symbol/SOLY' title='Soliton, Inc.'>SOLY</a> <font color=\"green\">+17.8%</font>) is up on below-average volume in response to <a href=\"https://seekingalpha.com/pr/17608003-soliton-announces-positive-results-demonstrated-longer-rap-treatment\" target=\"_blank\">new preclinical data</a> supporting longer treatment times with its Rapid Acoustic Pulse &#40;RAP&#41; device aimed at improving the appearance of cellulite.</li><li>The company says the treatment effect, called acoustic subcision which breaks up fat cells, helps explain the recent positive results from a <a href=\"https://seekingalpha.com/news/3476234-soliton-25-percent-ahead-shockwave-data-cellulite\" target=\"_blank\">proof-of-concept study</a> that showed a 20 - 47% improvement in Cellulite Severity Score following RAP treatment.</li><li>The new data showed that increased treatment time appeared to correlate with heightened acoustic subcision.</li><li>The company plans to file a 510(k) application with the FDA seeking clearance for the application. The RAP device is currently cleared for tattoo removal.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493283\" data-linked=\"Soliton up 18% on encouraging data supporting longer RAP treatment\" data-tweet=\"$SOLY - Soliton up 18% on encouraging data supporting longer RAP treatment https://seekingalpha.com/news/3493283-soliton-up-18-on-encouraging-data-supporting-longer-rap-treatment?source=tweet\" data-url=\"https://seekingalpha.com/news/3493283-soliton-up-18-on-encouraging-data-supporting-longer-rap-treatment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493282\" data-ts=\"1566310472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JCP\" target=\"_blank\">JCP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493282-j-c-penneyplus-10-after-chairman-antes-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">J.C. Penney +10% after chairman antes up</a></h4><ul> <li>It's only a few pennies really but J.C. Penney (NYSE:<a href='https://seekingalpha.com/symbol/JCP' title='J. C. Penney Company, Inc.'>JCP</a>) is <font color=\"green\">up 9.83%</font> to $0.65 after the company disclosed that Chairman Ronald Tysoe bought 1M shares.</li> <li>Tysoe is a real estate veteran who also sits on the board of Cintas, Taubman Centers and Canadian Imperial Bank of Commerce.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3493065-j-c-penney-perks-insider-buy\" target=\"_blank\">J.C. Penney perks up on insider buy</a> (Aug. 19)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493282\" data-linked=\"J.C. Penney +10% after chairman antes up\" data-tweet=\"$JCP - J.C. Penney +10% after chairman antes up https://seekingalpha.com/news/3493282-j-c-penneyplus-10-after-chairman-antes-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3493282-j-c-penneyplus-10-after-chairman-antes-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493276\" data-ts=\"1566309331\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493276-timeshare-sector-rallies-off-m-buzz\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Timeshare sector rallies off M&amp;A buzz</a></h4><ul> <li>Hilton Grand Vacations (NYSE:<a href='https://seekingalpha.com/symbol/HGV' title='Hilton Grand Vacations Inc.'>HGV</a>) is <font color=\"green\">up 10.0%</font> as investors latch on to the <a href=\"https://seekingalpha.com/news/3493197-hilton-grand-vacations-pops-takeover-story\" target=\"_blank\">NY Post report</a> of interest by Apollo Global Management.</li> <li>Timeshare peers Wyndham Destinations (NYSE:<a href='https://seekingalpha.com/symbol/WYND' title='Wyndham Destinations, Inc.'>WYND</a>) and Marriott Vacations (NYSE:<a href='https://seekingalpha.com/symbol/VAC' title='Marriott Vacations Worldwide Corporation'>VAC</a>) are also catching bids. WYND is <font color=\"green\">up 1.85%</font> in morning trading and VAC is <font color=\"green\">2.22% higher</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3493276\" data-linked=\"Timeshare sector rallies off M&amp;A buzz\" data-tweet=\"$HGV $WYND $VAC - Timeshare sector rallies off M&amp;A buzz https://seekingalpha.com/news/3493276-timeshare-sector-rallies-off-m-buzz?source=tweet\" data-url=\"https://seekingalpha.com/news/3493276-timeshare-sector-rallies-off-m-buzz\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493275\" data-ts=\"1566309325\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNO\" target=\"_blank\">VNO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493275-vornado-loses-bull-amid-oversupply-in-new-york-office-segment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vornado loses a bull amid oversupply in New York office segment</a></h4><ul><li>Vornado Realty Trust (<a href='https://seekingalpha.com/symbol/VNO' title='Vornado Realty Trust'>VNO</a> <font color='red'>-1%</font>) declines after Argus Resarch analyst Jacob Kilstein downgrades the stock to hold from buy, citing pressure from oversupply in the New York office segment.</li><li>Demand hasn't increased as much as expected even with incremental rent increases, Kilstein notes.</li><li>Argus's outlook for REITs isn't as positive as a few months ago due to expected slow pace of Fed interest rate cuts.</li><li>Cuts 2020 EPS estimate to $3.74 from $4.</li><li>Before this action, Sell-Side average rating was<a href=\"https://seekingalpha.com/symbol/VNO/ratings/sell-side-ratings\" target=\"_blank\"> Outperform</a> (5 Buy, 3 Outperform, 6 Hold, 1 Underperform).</li><li>See<a href=\"https://seekingalpha.com/symbol/VNO/peers/comparison\" target=\"_blank\"> peers' key stats comparison</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493275\" data-linked=\"Vornado loses a bull amid oversupply in New York office segment\" data-tweet=\"$VNO - Vornado loses a bull amid oversupply in New York office segment https://seekingalpha.com/news/3493275-vornado-loses-bull-amid-oversupply-in-new-york-office-segment?source=tweet\" data-url=\"https://seekingalpha.com/news/3493275-vornado-loses-bull-amid-oversupply-in-new-york-office-segment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493270\" data-ts=\"1566309187\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENDP\" target=\"_blank\">ENDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493270-endo-nearing-settlement-of-ohio-opioid-suit-shares-up-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endo nearing settlement of Ohio opioid suit; shares up 18%</a></h4><ul><li>Endo International (<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a> <font color=\"green\">+18.4%</font>) is up on below-average volume in early trade on the heels of its <a href=\"https://seekingalpha.com/pr/17608453-endo-announces-settlement-principle-resolve-track-1-opioid-cases\" target=\"_blank\">announcement </a>that subsidiaries Endo Pharmaceuticals, Endo Health Solutions, Par Pharmaceutical and Par Pharmaceutical Companies have agreed in principle to settle lawsuits brought by two counties and certain persons in Ohio related to their role in the opioid epidemic there.</li><li>Under the terms of the prospective settlement, Endo will pay $10M and provide up to $1M of its Vasostrict and Adrenalin products at no charge to the counties, all allocated by and between the counties at their sole discretion, with no admission of wrongdoing, fault or liability.</li><li>In the event of a comprehensive settlement of government-related opioid claims, the two counties will receive their respective amounts less the value of what they received under this settlement.</li><li>Opioid-related tickers: Teva Pharmaceutical Industries (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color=\"green\">+8.8%</font>), Mylan (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan N.V.'>MYL</a> <font color=\"green\">+2.3%</font>), Mallinckrodt (<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt plc'>MNK</a> <font color=\"green\">+10.7%</font>), Perrigo (<a href='https://seekingalpha.com/symbol/PRGO' title='Perrigo Company plc'>PRGO</a> <font color=\"green\">+0.6%</font>), Alkermes (<a href='https://seekingalpha.com/symbol/ALKS' title='Alkermes plc'>ALKS</a> <font color=\"green\">+0.7%</font>), Assertio Therapeutics (<a href='https://seekingalpha.com/symbol/ASRT' title='Assertio Therapeutics, Inc.'>ASRT</a> <font color=\"green\">+1.9%</font>), Nektar Therapeutics (<a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color=\"red\">-2.2%</font>), McKesson (<a href='https://seekingalpha.com/symbol/MCK' title='McKesson Corporation'>MCK</a> <font color=\"green\">+0.8%</font>), Cardinal Health (<a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health, Inc.'>CAH</a> <font color=\"green\">+1%</font>), AmerisourceBergen (<a href='https://seekingalpha.com/symbol/ABC' title='AmerisourceBergen Corporation'>ABC</a> <font color=\"green\">+0.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3493270\" data-linked=\"Endo nearing settlement of Ohio opioid suit; shares up 18%\" data-tweet=\"$ENDP $TEVA $MYL - Endo nearing settlement of Ohio opioid suit; shares up 18% https://seekingalpha.com/news/3493270-endo-nearing-settlement-of-ohio-opioid-suit-shares-up-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3493270-endo-nearing-settlement-of-ohio-opioid-suit-shares-up-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493269\" data-ts=\"1566308854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCEL\" target=\"_blank\">FCEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493269-new-chief-to-lead-fuelcell-restructuring\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New chief to lead FuelCell restructuring</a></h4><ul><li>FuelCell Energy (<a href='https://seekingalpha.com/symbol/FCEL' title='FuelCell Energy, Inc.'>FCEL</a> <font color='red'>-6.4%</font>) has <a href=\"https://seekingalpha.com/pr/17608372-fuelcell-energy-announces-jason-new-president-chief-executive-officer\" target=\"_blank\">appointed</a> Jason Few, who joined the board in November 2018, as its new President and CEO, effective as of August 26, 2019.</li><li>Few, along with the company\u2019s executive leadership team, will be responsible for the revitalization and advancement of FuelCell Energy, including its ongoing restructuring efforts.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493269\" data-linked=\"New chief to lead FuelCell restructuring\" data-tweet=\"$FCEL - New chief to lead FuelCell restructuring https://seekingalpha.com/news/3493269-new-chief-to-lead-fuelcell-restructuring?source=tweet\" data-url=\"https://seekingalpha.com/news/3493269-new-chief-to-lead-fuelcell-restructuring\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493259\" data-ts=\"1566308099\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAB\" target=\"_blank\">PLAB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493259-photronicsplus-6-after-revenue-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Photronics +6% after revenue beat</a></h4><ul><li>Photronics (NASDAQ:<a href='https://seekingalpha.com/symbol/PLAB' title='Photronics, Inc.'>PLAB</a>) <font color=\"green\">+6.3%</font> reports <a href=\"https://seekingalpha.com/news/3493130-photronics-eps-line-beats-revenue\" target=\"_blank\">Q3 results</a> that beat top-line estimates and met on EPS.</li><li>The in-line Q4 outlook sees revenue of $143-151M (consensus: $147.10M) and EPS of $0.11-0.17 (consensus: $0.12).</li><li><a href=\"https://seekingalpha.com/pr/17607771-photronics-reports-third-quarter-fiscal-2019-results\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493259\" data-linked=\"Photronics +6% after revenue beat\" data-tweet=\"$PLAB - Photronics +6% after revenue beat https://seekingalpha.com/news/3493259-photronicsplus-6-after-revenue-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3493259-photronicsplus-6-after-revenue-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493256\" data-ts=\"1566307830\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYOV\" target=\"_blank\">MYOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493256-myovant-advancing-orilissa-competitor-relugolix\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Myovant advancing Orilissa competitor relugolix</a></h4><ul><li>Myovant Sciences (NYSE:<a href='https://seekingalpha.com/symbol/MYOV' title='Myovant Sciences Ltd.'>MYOV</a>) <a href=\"https://seekingalpha.com/pr/17608167-myovant-sciences-completes-patient-recruitment-phase-3-spirit-2-study-evaluating-relugolix\" target=\"_blank\">completes enrollment</a> in the first of two Phase 3 replicate clinical trials, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03204331?titles=spirit+2&amp;lead=myovant&amp;phase=2&amp;rank=1\" target=\"_blank\">SPIRIT 2</a>, evaluating relugolix combo therapy in women with endometriosis-associated pain.</li><li>The co-primary endpoints are the proportion of responders based on daily assessment of non-menstrual pelvic pain and dysmenorrhea (menstrual cramps) at week 24.</li><li>Topline data should be available in Q1 2020 followed by results from SPIRIT 1 in Q2 2020.</li><li>The company expects to file a U.S. marketing application in Q4 seeking approval to use relugolix to treat women with heavy menstrual bleeding and uterine fibroids.</li><li>Relugolix will compete with AbbVie's (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) <a href=\"https://www.orilissa.com/\" target=\"_blank\">Orilissa</a> (elagolix).</li></ul><div class=\"tiny-share-widget\" data-id=\"3493256\" data-linked=\"Myovant advancing Orilissa competitor relugolix\" data-tweet=\"$MYOV $ABBV - Myovant advancing Orilissa competitor relugolix https://seekingalpha.com/news/3493256-myovant-advancing-orilissa-competitor-relugolix?source=tweet\" data-url=\"https://seekingalpha.com/news/3493256-myovant-advancing-orilissa-competitor-relugolix\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493255\" data-ts=\"1566307755\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493255-disneyminus-1_6-imperial-trims-target-on-football-look\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Disney -1.6% as Imperial trims target on football look</a></h4><ul>   <li>Disney (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) is <font color=\"red\">1.6% lower</font> premarket after a price target cut at Imperial Capital, which is looking at a tougher college football schedule.</li>    <li>\"ESPN simply faces a difficult comp in terms of gross ratings points and advertising CPMs,\" says Imperial's David Miller, and games have \"very little in terms of 'Power 5' flavor\" -- referring to matchups in the top college football conferences.</li>    <li>He also expects losses to continue in direct-to-consumer.</li>    <li>He's cut the price target to $140 from $147, trimming implied upside to 3.5%.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3493255\" data-linked=\"Disney -1.6% as Imperial trims target on football look\" data-tweet=\"$DIS - Disney -1.6% as Imperial trims target on football look https://seekingalpha.com/news/3493255-disneyminus-1_6-imperial-trims-target-on-football-look?source=tweet\" data-url=\"https://seekingalpha.com/news/3493255-disneyminus-1_6-imperial-trims-target-on-football-look\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493253\" data-ts=\"1566307558\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPR\" target=\"_blank\">TPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493253-baml-scratches-tapestry-from-us-1-list\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BAML scratches Tapestry from US 1 List</a></h4><ul> <li>Bank of America Merrill Lynch pulls Tapestry (NYSE:<a href='https://seekingalpha.com/symbol/TPR' title='Tapestry, Inc.'>TPR</a>) off its US 1 List, but keeps a Buy rating in place.</li> <li>The firm calls its US 1 List a collection of its best investment ideas that are drawn from the universe of Buy-rated U.S. stocks.</li> <li>Shares of TPR are <font color=\"green\">up 1.34%</font> premarket to $21.25 extending on yesterday's <a href=\"https://seekingalpha.com/news/3492954-tapestry-bounces-multi-year-low\" target=\"_blank\">recovery rally</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493253\" data-linked=\"BAML scratches Tapestry from US 1 List\" data-tweet=\"$TPR - BAML scratches Tapestry from US 1 List https://seekingalpha.com/news/3493253-baml-scratches-tapestry-from-us-1-list?source=tweet\" data-url=\"https://seekingalpha.com/news/3493253-baml-scratches-tapestry-from-us-1-list\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493245\" data-ts=\"1566306945\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493245-srpt-se-elan-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SRPT, SE, ELAN among premarket losers</a></h4><ul><li>Synlogic (NASDAQ:<a href='https://seekingalpha.com/symbol/SYBX' title='Synlogic, Inc.'>SYBX</a>) <font color=\"red\">-25%</font> in reaction to its decision to <a href=\"https://seekingalpha.com/news/3493200-synlogic-bails-hyperammonemia-candidate-shares-23-percent-premarket\" target=\"_blank\">terminate</a> development of SYNB1020 for the treatment of hyperammonemia.</li><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) <font color=\"red\">-17%</font> on <a href=\"https://seekingalpha.com/news/3493094-sarepta-minus-13-percent-fda-concerns-muscular-dystrophy-drug\" target=\"_blank\">FDA concerns</a> about muscular dystrophy drug.</li><li>Fabrinet (NYSE:<a href='https://seekingalpha.com/symbol/FN' title='Fabrinet'>FN</a>) <font color=\"red\">-17%</font> after <a href=\"https://seekingalpha.com/news/3493056-fabrinet-minus-12-percent-downside-outlook\" target=\"_blank\">downside outlook</a>.</li><li>Sea (NYSE:<a href='https://seekingalpha.com/symbol/SE' title='Sea Limited'>SE</a>) <font color=\"red\">-12%</font> on <a href=\"https://seekingalpha.com/news/3493142-sea-eps-2_35\" target=\"_blank\">Q2 earnings</a>.</li><li>TrovaGene (NASDAQ:<a href='https://seekingalpha.com/symbol/TROV' title='TrovaGene, Inc.'>TROV</a>) <font color=\"red\">-10%</font>.</li><li>Yuma Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/YUMA' title='Yuma Energy, Inc.'>YUMA</a>) <font color=\"red\">-10%</font>.</li><li>DPW Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/news/3493118-dpw-holdings-reports-q2-results\" target=\"_blank\">Q2 earnings</a>.</li><li>Miragen Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/MGEN' title='Miragen Therapeutics, Inc.'>MGEN</a>) <font color=\"red\">-8%</font>.</li><li>Elanco Animal Health (NYSE:<a href='https://seekingalpha.com/symbol/ELAN' title='Elanco Animal Health Incorporated'>ELAN</a>) <font color=\"red\">-7%</font> on <a href=\"https://seekingalpha.com/news/3493144-elanco-acquire-bayers-animal-health-unit-7_6b\" target=\"_blank\">acquisition</a> of Bayer's animal health unit.</li><li>iQIYI (NASDAQ:<a href='https://seekingalpha.com/symbol/IQ' title='iQIYI, Inc.'>IQ</a>) <font color=\"red\">-7%</font> on <a href=\"https://seekingalpha.com/news/3493071-iqiyi-eps-misses-0_04-revenue-line\" target=\"_blank\">Q2 eanings</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493245\" data-linked=\"SRPT, SE, ELAN among premarket losers\" data-tweet=\"$SYBX $SRPT $FN - SRPT, SE, ELAN among premarket losers https://seekingalpha.com/news/3493245-srpt-se-elan-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3493245-srpt-se-elan-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493242\" data-ts=\"1566306744\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493242-sdrl-bidu-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SDRL, BIDU among premarket gainers</a></h4><ul><li>Nabriva Therapeutics plc (NASDAQ:<a href='https://seekingalpha.com/symbol/NBRV' title='Nabriva Therapeutics plc'>NBRV</a>) <font color=\"green\">+23%</font>.</li><li>VIVUS (NASDAQ:<a href='https://seekingalpha.com/symbol/VVUS' title='VIVUS, Inc.'>VVUS</a>) <font color=\"green\">+19%</font> on <a href=\"https://seekingalpha.com/news/3493187-vivus-30-percent-premarket-positive-qsymia-data-gastric-sleeve-surgery\" target=\"_blank\">positive</a> Qsymia data in gastric sleeve surgery.</li><li>Seadrill (NYSE:<a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited'>SDRL</a>) <font color=\"green\">+17%</font> on <a href=\"https://seekingalpha.com/news/3493133-seadrill-eps-beats-0_48-misses-revenue\" target=\"_blank\">Q2 result</a>.</li><li>Soliton (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLY' title='Soliton, Inc.'>SOLY</a>) <font color=\"green\">+15%</font> on <a href=\"https://seekingalpha.com/pr/17608003-soliton-announces-positive-results-demonstrated-longer-rap-treatment\" target=\"_blank\">positive</a> results demonstrated from longer RAP treatment.</li><li>Hilton Grand Vacations (NYSE:<a href='https://seekingalpha.com/symbol/HGV' title='Hilton Grand Vacations Inc.'>HGV</a>) <font color=\"green\">+11%</font> on <a href=\"https://seekingalpha.com/news/3493197-hilton-grand-vacations-pops-takeover-story\" target=\"_blank\">takeover story</a>.</li><li>Baidu (NASDAQ:<a href='https://seekingalpha.com/symbol/BIDU' title='Baidu, Inc.'>BIDU</a>) <font color=\"green\">+9%</font> on <a href=\"https://seekingalpha.com/news/3493054-baidu-eps-beats-0_55-beats-revenue\" target=\"_blank\">Q2 results</a>.</li><li>One Stop Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/OSS' title='One Stop Systems, Inc.'>OSS</a>) <font color=\"green\">+8%</font> on <a href=\"https://seekingalpha.com/pr/17608175-oss-receives-5_5-million-flash-array-order-military-radar-application\" target=\"_blank\">receiving</a> $5.5M flash array order for military radar application.</li><li>Beyond Meat (NASDAQ:<a href='https://seekingalpha.com/symbol/BYND' title='Beyond Meat, Inc.'>BYND</a>) <font color=\"green\">+6%</font> on <a href=\"https://seekingalpha.com/news/3493203-jpmorgan-believer-beyond-meat\" target=\"_blank\">positive upgrade</a>.</li><li>Moderna (NASDAQ:<a href='https://seekingalpha.com/symbol/MRNA' title='Moderna, Inc.'>MRNA</a>) <font color=\"green\">+6%</font> as <a href=\"https://seekingalpha.com/news/3493038-moderna-zika-vaccine-candidate-fast-trackd-u-s-shares-5-percent-hours\" target=\"_blank\">Zika vaccine</a> candidate Fast Track'd in U.S.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493242\" data-linked=\"SDRL, BIDU among premarket gainers\" data-tweet=\"$NBRV $VVUS $SDRL - SDRL, BIDU among premarket gainers https://seekingalpha.com/news/3493242-sdrl-bidu-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3493242-sdrl-bidu-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493240\" data-ts=\"1566306668\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493240-sarepta-selloff-attractive-entry-nomura\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta selloff an attractive entry - Nomura</a></h4><ul><li>Nomura's Christopher Marai (Buy/$230) says the drop in Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) in reaction to the golodirsen CRL is a buying opportunity for bulls since the <a href=\"https://seekingalpha.com/news/3493094-sarepta-minus-13-percent-fda-concerns-muscular-dystrophy-drug\" target=\"_blank\">cited issues</a>, infection risk related to IV infusion ports and renal toxicity observed in preclinical models, are not surprises and represent no read-through risk to EXONDYS 51, casimersen or its gene therapy. No efficacy concerns were apparently mentioned.</li><li>Shares are down <font color=\"red\">18%</font> premarket on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493240\" data-linked=\"Sarepta selloff an attractive entry - Nomura\" data-tweet=\"$SRPT - Sarepta selloff an attractive entry - Nomura https://seekingalpha.com/news/3493240-sarepta-selloff-attractive-entry-nomura?source=tweet\" data-url=\"https://seekingalpha.com/news/3493240-sarepta-selloff-attractive-entry-nomura\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493239\" data-ts=\"1566306606\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LVS\" target=\"_blank\">LVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493239-argus-cools-on-las-vegas-sands\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Argus cools on Las Vegas Sands</a></h4><ul> <li>Argus Research drops Las Vegas Sands (NYSE:<a href='https://seekingalpha.com/symbol/LVS' title='Las Vegas Sands Corp.'>LVS</a>) to a Hold rating from Buy on concerns over a slowing Chinese economy.</li> <li>\"We expect nongaming operations (conventions, hotels and retail centers) to boost the company's revenue in Las Vegas, and to help offset weakness in the Las Vegas gaming market. At the same time, we expect a decline in the number of wealthy gamblers traveling to Macau as the Chinese economy slows,\" writes analyst John Staszak.</li> <li>Argus lowers its 2019 EPS estimate to $3.30 from $3.70 and the 2020 estimate to $3.60 from $4.00 to reflect new expectations for Macau. The long-term LVS earnings growth rate estimate is 14%.</li> <li>Argus might be in a holding pattern on Las Vegas Sands, but the <a href=\"https://seekingalpha.com/symbol/LVS/ratings/sell-side-ratings\" target=\"_blank\">sell-side consensus</a> is still Outperform.</li> <li>Shares of LVS are <font color=\"red\">down 0.90%</font> premarket to $54.18.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493239\" data-linked=\"Argus cools on Las Vegas Sands\" data-tweet=\"$LVS - Argus cools on Las Vegas Sands https://seekingalpha.com/news/3493239-argus-cools-on-las-vegas-sands?source=tweet\" data-url=\"https://seekingalpha.com/news/3493239-argus-cools-on-las-vegas-sands\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493237\" data-ts=\"1566306513\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RUN\" target=\"_blank\">RUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493237-residential-solar-stock-weakness-presents-opportunity-keybanc-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Residential solar stock weakness presents opportunity, KeyBanc says</a></h4><ul><li>Sunrun (NASDAQ:<a href='https://seekingalpha.com/symbol/RUN' title='Sunrun Inc.'>RUN</a>) <font color=\"green\">+1.9%</font> and Vivint Solar (NYSE:<a href='https://seekingalpha.com/symbol/VSLR' title='Vivint Solar, Inc.'>VSLR</a>) <font color=\"green\">+1.2%</font> pre-market after KeyBanc initiates coverage of the solar names with Overweight ratings, saying recent share weakness in residential solar stocks presents an attractive  entry point for investors.</li><li>RUN offers the best growth prospects, and VSLR offers the best margin of safety while also still trading at a discount to the value of its existing portfolio, says KeyBanc's Sophie Karp.</li><li>RUN's average <a href=\"https://seekingalpha.com/symbol/RUN/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Outperform, while both its <a href=\"https://seekingalpha.com/symbol/RUN/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors Rating</a> and <a href=\"https://seekingalpha.com/symbol/RUN/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> are Neutral.</li><li>VSLR's average <a href=\"https://seekingalpha.com/symbol/VSLR/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Buy, while its <a href=\"https://seekingalpha.com/symbol/VSLR/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is neutral.</li><li>ETF: <a href='https://seekingalpha.com/symbol/TAN' title='Invesco Solar Portfolio ETF'>TAN</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3493237\" data-linked=\"Residential solar stock weakness presents opportunity, KeyBanc says\" data-tweet=\"$RUN $VSLR $TAN - Residential solar stock weakness presents opportunity, KeyBanc says https://seekingalpha.com/news/3493237-residential-solar-stock-weakness-presents-opportunity-keybanc-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3493237-residential-solar-stock-weakness-presents-opportunity-keybanc-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493229\" data-ts=\"1566305974\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EIGR\" target=\"_blank\">EIGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493229-eiger-up-3-premarket-on-btd-tag-for-peginterferon-lambda-for-hdv-infection\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eiger up 3% premarket on BTD tag for peginterferon lambda for HDV infection</a></h4><ul><li>Eiger BioPharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/EIGR' title='Eiger BioPharmaceuticals, Inc.'>EIGR</a>) is up <font color=\"green\">3%</font> premarket in reaction to U.S. Breakthrough Therapy <a href=\"https://seekingalpha.com/pr/17607970-eiger-announces-fda-breakthrough-therapy-designation-peginterferon-lambda-treatment-hepatitis\" target=\"_blank\">designation </a>for peginterferon lambda (Lambda) for the treatment of hepatitis delta virus &#40;HDV&#41; infection.</li><li>Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.</li>                   <li>Eiger licensed worldwide rights to Lambda from Bristol-Myers Squibb.</li><li>Lambda is a type III interferon that stimulates immune responses that are critical for the development of host protection during viral infections.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493229\" data-linked=\"Eiger up 3% premarket on BTD tag for peginterferon lambda for HDV infection\" data-tweet=\"$EIGR - Eiger up 3% premarket on BTD tag for peginterferon lambda for HDV infection https://seekingalpha.com/news/3493229-eiger-up-3-premarket-on-btd-tag-for-peginterferon-lambda-for-hdv-infection?source=tweet\" data-url=\"https://seekingalpha.com/news/3493229-eiger-up-3-premarket-on-btd-tag-for-peginterferon-lambda-for-hdv-infection\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493228\" data-ts=\"1566305803\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NCNA\" target=\"_blank\">NCNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493228-nucanas-acelarin-fails-to-beat-chemo-in-pancreatic-cancer-study-shares-down-20-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NuCana&#39;s Acelarin fails to beat chemo in pancreatic cancer study; shares down 20% premarket</a></h4><ul><li>Thinly traded micro cap NuCana plc (NASDAQ:<a href='https://seekingalpha.com/symbol/NCNA' title='NuCana plc'>NCNA</a>) slumps <font color=\"red\">20% </font>premarket on light volume in reaction to its decision to <a href=\"https://seekingalpha.com/pr/17608063-enrollment-independent-investigator-sponsored-phase-iii-metastatic-pancreatic-study-acelarate\" target=\"_blank\">suspend enrollment</a> in the Phase 3 <a href=\"https://clinicaltrials.gov/ct2/show/NCT03610100?cond=Pancreatic+Cancer&amp;titles=acelarate&amp;phase=2&amp;rank=1\" target=\"_blank\">ACELARATE </a>study evaluating Acelarin as monotherapy compared to gemcitabine in metastatic pancreatic cancer patients.</li><li>The company decided to stop recruitment after a prespecified futility analysis by the independent Safety and Data Monitoring Committee showed that the efficacy endpoint was unlikely to be met. It plans to allow the data to mature and conduct additional subgroup analyses on the 25 participants who are receiving or have received Acelarin.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493228\" data-linked=\"NuCana&#39;s Acelarin fails to beat chemo in pancreatic cancer study; shares down 20% premarket\" data-tweet=\"$NCNA - NuCana&#39;s Acelarin fails to beat chemo in pancreatic cancer study; shares down 20% premarket https://seekingalpha.com/news/3493228-nucanas-acelarin-fails-to-beat-chemo-in-pancreatic-cancer-study-shares-down-20-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3493228-nucanas-acelarin-fails-to-beat-chemo-in-pancreatic-cancer-study-shares-down-20-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493225\" data-ts=\"1566305202\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TJX\" target=\"_blank\">TJX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493225-tjx-companiesminus-4-after-comp-sales-disappoint\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TJX Companies -4% after comp sales disappoint</a></h4><ul> <li>TJX Companies (NYSE:<a href='https://seekingalpha.com/symbol/TJX' title='The TJX Companies, Inc.'>TJX</a>) reports comparable sales rose 2.0% in <a href=\"https://seekingalpha.com/pr/17608143-tjx-companies-inc-reports-q2-fy20-results-eps-0_62-high-end-guidance\" target=\"_blank\">Q2</a> to fall short of the consensus expectation for a 3.1% increase. A flat comp from the Home Goods chain held back the retailer's performance during the quarter.</li> <li>TJX's gross margin rate came in at 28.2% of sales vs. 28.3% consensus and 28.9% a year ago. Consolidated pretax profit margin was 10.4% vs. 10.6% a year ago.</li> <li>Looking ahead, TJX sees Q3 EPS of $0.63 to $0.65 vs. $0.68 consensus and full-year EPS of $2.56 to $2.61 vs. $2.63 consensus. \"The third quarter is off to a solid start. We feel great about the terrific availability we are seeing in the marketplace for branded, quality merchandise and our ability to capitalize on the opportunities,\" says CEO Ernie Herrman.</li> <li>Shares of TJX are <font color=\"red\">down 3.55%</font> in premarket action to $49.72.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3493214-tjx-eps-line-misses-revenue\" target=\"_blank\">TJX EPS in-line, misses on revenue</a> (Aug. 20)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493225\" data-linked=\"TJX Companies -4% after comp sales disappoint\" data-tweet=\"$TJX - TJX Companies -4% after comp sales disappoint https://seekingalpha.com/news/3493225-tjx-companiesminus-4-after-comp-sales-disappoint?source=tweet\" data-url=\"https://seekingalpha.com/news/3493225-tjx-companiesminus-4-after-comp-sales-disappoint\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493223\" data-ts=\"1566305051\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMU\" target=\"_blank\">IMMU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493223-piper-upgrades-abbvie-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper upgrades AbbVie in premarket analyst action</a></h4><ul><li>Immunomedics (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a>) initiated with Overweight rating and $28 price target at Cantor Fitzgerald.</li><li>SCYNEXIS (NASDAQ:<a href='https://seekingalpha.com/symbol/SCYX' title='SCYNEXIS, Inc.'>SCYX</a>) initiated with Buy rating and $5 (367% upside) price target at Brookline Capital. Shares up <font color=\"green\">5% </font>premarket.</li><li>Targovax AS ((TRVX NO)) initiated with Buy rating and 19 kroner (236% upside) price target at H.C. Wainwright.</li><li>AbbVie (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) upgraded to Overweight with an $80 (20% upside) price target at Piper Jaffray. Shares up <font color=\"green\">2%</font> premarket.</li><li>REGENXBIO (NASDAQ:<a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO Inc.'>RGNX</a>) upgraded to Market Perform with a $37 (flat) price target at SVB Leerink. Shares up <font color=\"green\">3%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493223\" data-linked=\"Piper upgrades AbbVie in premarket analyst action\" data-tweet=\"$IMMU $SCYX $ABBV - Piper upgrades AbbVie in premarket analyst action https://seekingalpha.com/news/3493223-piper-upgrades-abbvie-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3493223-piper-upgrades-abbvie-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493210\" data-ts=\"1566304077\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MKC\" target=\"_blank\">MKC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493210-mccormickminus-1-after-jpmorgan-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McCormick -1% after JPMorgan cut</a></h4><ul> <li>JPMorgan drops McCormick (NYSE:<a href='https://seekingalpha.com/symbol/MKC' title='McCormick & Company, Incorporated'>MKC</a>) to an Underweight rating from Neutral.</li> <li>Analyst Ken Goldman notes MKC's fundamentals are attractive relative to packaged food peers and the spice category is strong, but thinks the magnitude of margin expansion experienced over the past year is unlikely to recur, and the stock\u2019s much higher-than-average valuation looks stretched to us.</li> <li>M&amp;A is seen as a positive catalyst for the shares, especially after the success of the French's / Frank's RedHot acquisition.</li><li>JPMorgan sets a price target of $154 vs. the <a href=\"https://seekingalpha.com/symbol/MKC/ratings/sell-side-ratings\" target=\"_blank\">average sell-side PT</a> of $151.67.</li> <li>Shares of MKC are <font color=\"red\">down 0.96%</font> premarket to $166.94.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493210\" data-linked=\"McCormick -1% after JPMorgan cut\" data-tweet=\"$MKC - McCormick -1% after JPMorgan cut https://seekingalpha.com/news/3493210-mccormickminus-1-after-jpmorgan-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3493210-mccormickminus-1-after-jpmorgan-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493207\" data-ts=\"1566303702\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPB\" target=\"_blank\">CPB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493207-jpmorgan-warms-up-to-campbell-soup\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan warms up to Campbell Soup</a></h4><ul> <li>JPMorgan upgrades Campbell Soup (NYSE:<a href='https://seekingalpha.com/symbol/CPB' title='Campbell Soup Company'>CPB</a>) to a Neutral rating from Underweight.</li> <li>\"On the positive side, sales are likely to improve this winter, the stock is no longer expensive versus the group, and LNCE-related synergies are flowing through nicely. On the less positive side, we do not have a valuation argument for a constructive rating, the soup category remains structurally challenged, and CPB is still running three separate DSD systems (a lot of complexity),\" notes analyst Ken Goldman.</li> <li>JPMorgan sets a price target of $41</li> <li>Shares of CPB are <font color=\"green\">up 0.58%</font> premarket to $43.44.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493207\" data-linked=\"JPMorgan warms up to Campbell Soup\" data-tweet=\"$CPB - JPMorgan warms up to Campbell Soup https://seekingalpha.com/news/3493207-jpmorgan-warms-up-to-campbell-soup?source=tweet\" data-url=\"https://seekingalpha.com/news/3493207-jpmorgan-warms-up-to-campbell-soup\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493203\" data-ts=\"1566303409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BYND\" target=\"_blank\">BYND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493203-jpmorgan-believer-in-beyond-meat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan a believer in Beyond Meat</a></h4><ul> <li>JPMorgan takes Beyond Meat (NASDAQ:<a href='https://seekingalpha.com/symbol/BYND' title='Beyond Meat, Inc.'>BYND</a>) to an Overweight rating from Neutral as it points to the potential for the company to acquire new food service customers. The analyst team also makes the case that valuation on Beyond Meat is attractive on a long-term view.</li> <li>The firm is also positive on the near term with new chains selling Beyond Burger products. \"We thus think the potential for sales to keep beating consensus estimates is legitimate,\" advises JP.</li> <li>JP assigns a price target of $189 to BYND vs. the sell-side average PT of $160.14.</li> <li>Shares of Beyond Meat are <font color=\"green\">up 7.15%</font> premarket to $154.84.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493203\" data-linked=\"JPMorgan a believer in Beyond Meat\" data-tweet=\"$BYND - JPMorgan a believer in Beyond Meat https://seekingalpha.com/news/3493203-jpmorgan-believer-in-beyond-meat?source=tweet\" data-url=\"https://seekingalpha.com/news/3493203-jpmorgan-believer-in-beyond-meat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493200\" data-ts=\"1566303097\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYBX\" target=\"_blank\">SYBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493200-synlogic-bails-on-hyperammonemia-candidate-shares-down-23-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synlogic bails on hyperammonemia candidate; shares down 23% premarket</a></h4><ul><li>Thinly traded micro cap Synologic (NASDAQ:<a href='https://seekingalpha.com/symbol/SYBX' title='Synlogic, Inc.'>SYBX</a>) is down <font color=\"red\">23% </font>premarket on light volume in reaction to its <a href=\"https://seekingalpha.com/pr/17607767-synlogic-discontinues-development-synb1020-treat-hyperammonemia\" target=\"_blank\">decision</a> to terminate development of SYNB1020 for the treatment of hyperammonemia (excess ammonia in the blood). The company decided to take action after an interim analysis of a Phase 1/2 study failed to show a treatment effect.</li><li>Detailed results will be submitted for presentation at a future medical conference.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493200\" data-linked=\"Synlogic bails on hyperammonemia candidate; shares down 23% premarket\" data-tweet=\"$SYBX - Synlogic bails on hyperammonemia candidate; shares down 23% premarket https://seekingalpha.com/news/3493200-synlogic-bails-on-hyperammonemia-candidate-shares-down-23-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3493200-synlogic-bails-on-hyperammonemia-candidate-shares-down-23-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493197\" data-ts=\"1566302747\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493197-hilton-grand-vacations-pops-on-takeover-story\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hilton Grand Vacations pops on takeover story</a></h4><ul> <li>Hilton Grand Vacation (NYSE:<a href='https://seekingalpha.com/symbol/HGV' title='Hilton Grand Vacations Inc.'>HGV</a>) could be an acquisition target of PE firm Apollo Global (NYSE:<a href='https://seekingalpha.com/symbol/APO' title='Apollo Global Management, LLC'>APO</a>), according to New York Post.</li> <li>Sources indicate that Apollo could bid as much as $36 per share.</li> <li>Shares of HGV are <font color=\"green\">up 13.48%</font> premarket to $32.00 vs. the 52-week trading range of $24.16 to $33.99.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493197\" data-linked=\"Hilton Grand Vacations pops on takeover story\" data-tweet=\"$HGV $APO - Hilton Grand Vacations pops on takeover story https://seekingalpha.com/news/3493197-hilton-grand-vacations-pops-on-takeover-story?source=tweet\" data-url=\"https://seekingalpha.com/news/3493197-hilton-grand-vacations-pops-on-takeover-story\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493188\" data-ts=\"1566302419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JMIA\" target=\"_blank\">JMIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493188-jumiaplus-4-bear-steps-to-sidelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jumia +4% as bear steps to sidelines</a></h4><ul><li>Morgan Stanley upgrades Jumia Technologies (NYSE:<a href='https://seekingalpha.com/symbol/JMIA' title='Jumia Technologies AG'>JMIA</a>) from Underweight to Equal-Weight citing the 40% pullback since the May earnings report. Jumia will report <a href=\"https://seekingalpha.com/symbol/JMIA/earnings\" target=\"_blank\">Q2 results</a> tomorrow.</li><li>Analyst Brian Nowak sees the potential for negative revisions around the October IPO lockup expiration, and he sees the bear case as more likely than the bull case. But Nowak still sees \"strategic and scarcity value associated with the asset.\"</li><li>Price target drops from $22 to $13.</li><li>Jumia is<font color=\"green\"> up 3.8%</font> pre-market to $16. The company has a Hold average <a href=\"https://seekingalpha.com/symbol/JMIA/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493188\" data-linked=\"Jumia +4% as bear steps to sidelines\" data-tweet=\"$JMIA - Jumia +4% as bear steps to sidelines https://seekingalpha.com/news/3493188-jumiaplus-4-bear-steps-to-sidelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3493188-jumiaplus-4-bear-steps-to-sidelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493187\" data-ts=\"1566302404\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VVUS\" target=\"_blank\">VVUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493187-vivus-up-30-premarket-on-positive-qsymia-data-in-gastric-sleeve-surgery\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vivus up 30% premarket on positive Qsymia data in gastric sleeve surgery</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17607923-new-pilot-clinical-study-results-demonstrate-addition-vivus-qsymia-gastric-sleeve-surgery\" target=\"_blank\">Results </a>from a pilot study conducted at the Wake Forest School of Medicine evaluating VIVUS' (NASDAQ:<a href='https://seekingalpha.com/symbol/VVUS' title='VIVUS, Inc.'>VVUS</a>) Qsymia (phentermine and topiramate extended-release &#40;ER&#41; capsules, administered before and after laparoscopic sleeve gastrectomy via continuous intravenous infusion &#40;CIV&#41;, showed that patients lost more weight and had a greater probability of achieving a body mass index &#40;BMI&#41; of less than 40 compared with patients undergoing surgery alone without anti-obesity medication.</li><li>25 subjects with a BMI of at least 50 (extremely obese) participated in the study. Patients in the experimental arm received a dose of 3.75/23 mg of Qsymia once daily for two weeks then 7.5/46 mg once daily. They were tapered off the medication starting two weeks prior to surgery then resumed at 7.5/46 mg daily for one month following the procedure.</li><li>Baseline BMI in the experimental group was 61.2 ± 7.1 kg/m2 compared with 57.0 ± 5.6 kg/m2 in the control group. At month 24, mean BMI was 33.8 kg/m2 in the experimental group vs. 42 kg/m2 for control.</li><li>Larger studies are next up if the company decides to advance development for this use.</li><li>Shares are up <font color=\"green\">30%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493187\" data-linked=\"Vivus up 30% premarket on positive Qsymia data in gastric sleeve surgery\" data-tweet=\"$VVUS - Vivus up 30% premarket on positive Qsymia data in gastric sleeve surgery https://seekingalpha.com/news/3493187-vivus-up-30-premarket-on-positive-qsymia-data-in-gastric-sleeve-surgery?source=tweet\" data-url=\"https://seekingalpha.com/news/3493187-vivus-up-30-premarket-on-positive-qsymia-data-in-gastric-sleeve-surgery\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493180\" data-ts=\"1566301374\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FN\" target=\"_blank\">FN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493180-fabrinet-targets-trimmed-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fabrinet targets trimmed after earnings</a></h4><ul><li>Analysts weigh in after Fabrinet's (NYSE:<a href='https://seekingalpha.com/symbol/FN' title='Fabrinet'>FN</a>) <a href=\"https://seekingalpha.com/news/3493056-fabrinet-minus-12-percent-downside-outlook\" target=\"_blank\">Q4 report</a> with downside Q1 guidance.</li><li>Piper Jaffray maintains an Overweight rating but lowers the target from $69 to $64, citing the lower earnings estimates.</li><li>The firm calls Fabrinet \"one of the better ways to play the optical market\" and expects sustained strength in Telco optics. Piper sees the Huawei-related issues as short-term headwinds.</li><li>B. Riley stays on the sidelines and trims the target from $56 to $54. The firm's long-term concern is that sales to Huawei could suffer from China's \"de-Americanization of its supply chain.\"</li><li>Fabrinet shares are <font color=\"red\">down 16%</font> pre-market to $47.44. The firm has an Outperform average <a href=\"https://seekingalpha.com/symbol/FN/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493180\" data-linked=\"Fabrinet targets trimmed after earnings\" data-tweet=\"$FN - Fabrinet targets trimmed after earnings https://seekingalpha.com/news/3493180-fabrinet-targets-trimmed-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3493180-fabrinet-targets-trimmed-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:42 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493179\" data-ts=\"1566301198\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SDRL\" target=\"_blank\">SDRL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493179-seadrill-narrows-loss-sees-improving-trends\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Seadrill narrows loss, sees some improving trends</a></h4><ul><li>Seadrill (NYSE:<a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited'>SDRL</a>) <font color=\"green\">+11%</font> pre-market after reporting a narrower than expected <a href=\"https://seekingalpha.com/news/3493133-seadrill-eps-beats-0_48-misses-revenue\" target=\"_blank\">Q2 loss</a> and <a href=\"https://www.offshoreenergytoday.com/seadrill-posts-206m-2q-loss-long-term-work-dayrates-improving/\" target=\"_blank\">seeing continued improvement</a> in Q3.</li><li>SDRL says it made $69M in Q2 adjusted EBITDA, above the $55M it forecast in May, and sees Q3 adjusted EBITDA of $70M-$75M vs. $61M analyst consensus estimate.</li><li>Q2 operating revenues totaled $321M, down 8% from  $348M in the year-earlier quarter, and rig contract revenues fell 18% to $253M from $311M a year ago; order backlog at June 30 was ~$1.9B.</li><li>SDRL says the spot market for short term work remains competitive and rates for longer-term work are improving.</li><li>SDRL says it sees \"pockets of strength in the markets for harsh environment units  and high-end ultra-deepwater drillships, with marketed utilization  approaching 90%. The improvements in forward pricing and utilization are  leading indicators that the recovery is progressing, and we believe  benign environment floater fixtures made in 2018 marked the low point.\"</li><li>The company also sees improving trends in the premium jack-up market, with marketed utilization  above 80% and rates trending towards $100K/day, and says \"while we are committed to  continuing our disciplined approach to jack-up reactivations, we believe  there are near term opportunities for some of our idle units.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3493179\" data-linked=\"Seadrill narrows loss, sees some improving trends\" data-tweet=\"$SDRL - Seadrill narrows loss, sees some improving trends https://seekingalpha.com/news/3493179-seadrill-narrows-loss-sees-improving-trends?source=tweet\" data-url=\"https://seekingalpha.com/news/3493179-seadrill-narrows-loss-sees-improving-trends\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493178\" data-ts=\"1566301118\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CC\" target=\"_blank\">CC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493178-chemoursplus-3_8-on-susquehanna-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chemours +3.8% on Susquehanna upgrade</a></h4><ul><li>Susquehanna analyst Donald Carson upgrades Chemours (NYSE:<a href='https://seekingalpha.com/symbol/CC' title='The Chemours Company'>CC</a>) to Positive from Neutral, giving shares a <font color=\"green\">3.8% boost</font> to $13.44/share premarket.</li><li>He still lowered the stock's price target to $18 from $37, implying a 39% increase from yesterday's close.</li><li>Source: Bloomberg First Word</li></ul><div class=\"tiny-share-widget\" data-id=\"3493178\" data-linked=\"Chemours +3.8% on Susquehanna upgrade\" data-tweet=\"$CC - Chemours +3.8% on Susquehanna upgrade https://seekingalpha.com/news/3493178-chemoursplus-3_8-on-susquehanna-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3493178-chemoursplus-3_8-on-susquehanna-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493177\" data-ts=\"1566300901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLDC\" target=\"_blank\">CLDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493177-china-lending-gets-deficiency-notice-from-nasdaq\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China Lending gets deficiency notice from Nasdaq</a></h4><ul><li>China Lending (NASDAQ:<a href='https://seekingalpha.com/symbol/CLDC' title='China Lending Corporation'>CLDC</a>) <a href=\"https://seekingalpha.com/pr/17607841-china-lending-receives-nasdaq-minimum-bid-price-continued-listing-deficiency-notice\" target=\"_blank\">receives a notification</a> from Nasdaq advising the company that it no longer meets the minimum $1.00 per share Nasdaq continued listing requirement.</li><li>CLDC has until Feb. 11, 2020 to regain compliance.</li><li>The company intends to continue to monitor the bid price for its common stock. </li><li>If its common shares do not trade at a level that is likely to regain compliance with the Nasdaq requirements, China Lending's board will consider alternative options that may be available to achieve compliance.</li><li>CLDC <font color=\"green\">rises 11% </font>in premarket trading to 70 cents per share.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493177\" data-linked=\"China Lending gets deficiency notice from Nasdaq\" data-tweet=\"$CLDC - China Lending gets deficiency notice from Nasdaq https://seekingalpha.com/news/3493177-china-lending-gets-deficiency-notice-from-nasdaq?source=tweet\" data-url=\"https://seekingalpha.com/news/3493177-china-lending-gets-deficiency-notice-from-nasdaq\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493169\" data-ts=\"1566300521\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDT\" target=\"_blank\">MDT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493169-medtronicplus-2-premarket-on-fiscal-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Medtronic +2% premarket on fiscal Q1 results</a></h4><ul><li>Medtronic (<a href='https://seekingalpha.com/symbol/MDT' title='Medtronic plc'>MDT</a>) <a href=\"https://seekingalpha.com/pr/17607819-medtronic-reports-first-quarter-financial-results\" target=\"_blank\">Q1 results</a>: Revenues: $7,493M (+1.5%); Cardiac &amp; Vascular Group: $2,790M (-0.7%); Minimally Invasive Therapies Group: $2,100M (+2.3%); Restorative Therapies Group: $2,012M (+3.2%); Diabetes Group: $626M (+3.5%).</li><li>Net Income: $864M (-19.6%); Non-GAAP Net Income: $1,703M (+6.4%); EPS: $0.64 (-19.0%); Non-GAAP EPS: $1.26 (+7.7%); CF Ops: $1,510M (-11.3%).</li><li><strong>Fiscal 2020 Guidance</strong>: Revenue growth (organic): ~4.0% (unch); non-GAAP EPS: $5.54 - 5.60 from $5.44 - 5.50.</li><li>Shares are up <font color=\"green\">2%</font> premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3493145-medtronic-eps-beats-0_07-beats-revenue\" target=\"_blank\">Medtronic EPS beats by $0.07, beats on revenue</a> (Aug. 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3493169\" data-linked=\"Medtronic +2% premarket on fiscal Q1 results\" data-tweet=\"$MDT - Medtronic +2% premarket on fiscal Q1 results https://seekingalpha.com/news/3493169-medtronicplus-2-premarket-on-fiscal-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3493169-medtronicplus-2-premarket-on-fiscal-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493164\" data-ts=\"1566300017\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HPQ\" target=\"_blank\">HPQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493164-citi-downgrades-hp-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citi downgrades HP ahead of earnings</a></h4><ul><li>Update with more details from the downgrade:</li><li>Analyst Jim Suva says expectations for a H2 recovery in IT Enterprise spending will likely become more muted due to the macro backdrop.</li><li>Suva says PCs could see an upside from increased demand ahead of the China tariffs, though that could wane in the coming quarters as Windows 7 is set to expire early next year.</li><li>Original post: Citi downgrades HP (NYSE:<a href='https://seekingalpha.com/symbol/HPQ' title='HP Inc.'>HPQ</a>) from Buy to Neutral and lowers the target to $21.</li><li>HP will report earnings on August 22. Consensus estimates <a href=\"https://seekingalpha.com/symbol/HPQ/earnings\" target=\"_blank\">expect </a>$14.59B in revenue with $0.55 EPS.</li><li>HP shares are <font color=\"red\">down 1.9% </font>pre-market to $18.84. The company has a Neutral <a href=\"https://seekingalpha.com/symbol/HPQ/ratings/quant-ratings\" target=\"_blank\">Quant rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493164\" data-linked=\"Citi downgrades HP ahead of earnings\" data-tweet=\"$HPQ - Citi downgrades HP ahead of earnings https://seekingalpha.com/news/3493164-citi-downgrades-hp-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3493164-citi-downgrades-hp-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493159\" data-ts=\"1566299367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KSS\" target=\"_blank\">KSS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493159-kohlsplus-4-after-profit-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kohl&#39;s +4% after profit beat</a></h4><ul> <li>Kohl's (NYSE:<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a>) reports comparable sales fell 2.9% in Q2 vs. -2.4% consensus, although they turned positive during the last six weeks of the quarter with 1% growth.</li> <li>\"This positive trend has continued into August driven by a successful start to the back-to-school season. We are confident that our upcoming brand launches, program expansions, and increased traffic from the Amazon returns program will incrementally contribute to our performance during the balance of the year and beyond,\" says Kohl's CEO Michelle Glass.</li> <li>Gross margin fell 70 bps to 38.8% of sales during the quarter vs. 39.2% consensus.</li> <li>Looking ahead, Kohl's management reaffirms full-year profit guidance for EPS of $5.15 to $5.45 vs. $5.23 consensus.</li> <li>Shares of Kohl's are <font color=\"green\">up 4.21%</font> premarket to $50.23.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3493152-kohls-eps-beats-0_02-beats-revenue\" target=\"_blank\">Kohl's EPS beats by $0.02, beats on revenue</a> (Aug. 20)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3493159\" data-linked=\"Kohl&#39;s +4% after profit beat\" data-tweet=\"$KSS - Kohl&#39;s +4% after profit beat https://seekingalpha.com/news/3493159-kohlsplus-4-after-profit-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3493159-kohlsplus-4-after-profit-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493153\" data-ts=\"1566299070\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZN\" target=\"_blank\">AZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493153-astrazenecas-farxiga-shows-cv-benefit-in-late-stage-heart-failure-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AstraZeneca&#39;s Farxiga shows CV benefit in late-stage heart failure study</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17607826-farxiga-met-primary-endpoint-landmark-phase-iii-dapa-hf-trial-treatment-patients-heart\" target=\"_blank\">Results </a>from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03036124?term=dapa-hf&amp;rank=1\" target=\"_blank\">DAPA-HF</a>, evaluating the effect of AstraZeneca's (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca PLC'>AZN</a>) Farxiga (dapagliflozin) on the rate of worsening heart failure or cardiovascular &#40;CV&#41; death in patients with chronic heart failure with reduced ejection fraction showed a treatment benefit. The trial met the primary endpoint of a statistically significant and clinically meaningful reduction in CV death or worsening of heart failure (defined as an urgent care visit or hospitalization) compared to placebo. Study participants included those with and without type 2 diabetes.</li><li>Complete data will be reviewed with regulatory authorities as soon as possible and submitted for presentation at a future medical conference.</li><li>The FDA approved the SGLT2 inhibitor in January 2014 for type 2 diabetes.</li><li>No new safety signals were observed.</li><li>Shares are up <font color=\"green\">2%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493153\" data-linked=\"AstraZeneca&#39;s Farxiga shows CV benefit in late-stage heart failure study\" data-tweet=\"$AZN - AstraZeneca&#39;s Farxiga shows CV benefit in late-stage heart failure study https://seekingalpha.com/news/3493153-astrazenecas-farxiga-shows-cv-benefit-in-late-stage-heart-failure-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3493153-astrazenecas-farxiga-shows-cv-benefit-in-late-stage-heart-failure-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3493144\" data-ts=\"1566297965\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELAN\" target=\"_blank\">ELAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3493144-elanco-to-acquire-bayers-animal-health-unit-for-7_6b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Elanco to acquire Bayer&#39;s animal health unit for $7.6B</a></h4><ul><li>Elanco Animal Health (NYSE:<a href='https://seekingalpha.com/symbol/ELAN' title='Elanco Animal Health Incorporated'>ELAN</a>) has <a href=\"https://seekingalpha.com/pr/17607746-elanco-announces-agreement-acquire-bayer-s-animal-health-business\" target=\"_blank\">agreed to acquire</a> Bayer's (<a href='https://seekingalpha.com/symbol/BAYRY' title='Bayer Aktiengesellschaft'>OTCPK:BAYRY</a>) animal health business in a cash and stock transaction. Specifically, Bayer will receive $5.32B in cash plus ~68M Elanco common shares valued at $2.28B.</li><li>Elanco plans to fund the cash portion with new debt and equity. When the deal closes in mid-2020, it expects to have a non-GAAP EBITDA leverage ratio of ~5x. Gross debt to non-GAAP EBITDA should drop to less than 3x by the end of 2022.</li><li>Mid-single-digit top line growth should continue.</li><li>Elanco will host a conference call this morning at 8:00 am ET to discuss the transaction.</li><li>ELAN is down <font color=\"red\">3%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3493144\" data-linked=\"Elanco to acquire Bayer&#39;s animal health unit for $7.6B\" data-tweet=\"$ELAN $BAYRY - Elanco to acquire Bayer&#39;s animal health unit for $7.6B https://seekingalpha.com/news/3493144-elanco-to-acquire-bayers-animal-health-unit-for-7_6b?source=tweet\" data-url=\"https://seekingalpha.com/news/3493144-elanco-to-acquire-bayers-animal-health-unit-for-7_6b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}